http://connection.asco.org RSS feeds for ASCO Connection – professional networking for ASCO’s worldwide oncology community 60 http://connection.asco.org/Magazine/Article/ID/3539/Daniel-G-Haller-MD-Appointed-First-Editor-in-Chief-of-ASCO-University.aspx#Comments 0 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=141&ModuleID=498&ArticleID=3539 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=3539&PortalID=0&TabID=141 http://connection.asco.org/Magazine/Article/ID/3539/Daniel-G-Haller-MD-Appointed-First-Editor-in-Chief-of-ASCO-University.aspx Daniel G. Haller, MD, a widely recognized researcher in gastrointestinal malignancies, respected editor, and long-time ASCO member and volunteer, has been appointed the first Editor-in-Chief of ASCO University®. Dr. Haller’s three-year term began in March 2013. ASCO saw a clear need for dedicated member leadership and oversight of ASCO University’s educational materials as the number of ASCO University courses and topic areas continue to expand and as cancer information becomes increasingly complex. Dr. Haller, who served as Editor in Chief of the Journal of Clinical Oncology from 2001-2011, believes his experience in the sphere of academic journals will translate nicely to his role and work with the Editorial Board for ASCO University. Dr. Haller explains, “We want to stay ahead of the curve in terms of learning modalities and continue to grow in areas such as mobile apps to provide different opportunities for lifelong learning.”  Currently, Dr. Haller is a Professor of Medicine at the University of Pennsylvania School of Medicine, and he is the Attending Physician at the Hospital of the University of Pennsylvania. He earned his medical degree from the University of Pittsburgh, and he completed both his residency and fellowship at Georgetown University Hospital. It is important, Dr. Haller noted, that members guide the growth of ASCO University. “The Editorial Board will be providing a lot of input—as members and oncologists ourselves, we understand the educational needs that we all share. But I plan to keep my ear to the ground to find out what people want, and I hope to get a lot of feedback,” he said. Dr. Haller is joined by a group of seven Associate Editors: Aditya Bardia, MD, of Massachusetts General Hospital; Quyen Chu, MD, of Louisiana State University Health Sciences Center; Jill Gilbert, MD, of Vanderbilt University; David Graham, MD, of Carle Clinic Association; Heather Hylton, PA-C, of Memorial Sloan-Kettering Cancer Center; Benjamin Levy, MD, Beth Israel Hospital; and Bhoomi Mehrotra, MD of St. Francis Hospital.  The Editorial Board encourages users to provide feedback and suggestions based on the current ASCO University content by submitting an e-mail to university@asco.org.   ascoadmin Mon, 20 May 2013 14:15:58 GMT f1397696-738c-4295-afcd-943feb885714:3539 http://connection.asco.org/Magazine/Article/ID/3536/ASCO-University-New-Leaders-New-Avenues-for-Learning.aspx#Comments 0 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=141&ModuleID=498&ArticleID=3536 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=3536&PortalID=0&TabID=141 http://connection.asco.org/Magazine/Article/ID/3536/ASCO-University-New-Leaders-New-Avenues-for-Learning.aspx The first Editorial Board led by Daniel G. Haller, MD, of Abramson Cancer Center, has recently been formed to provide dedicated member leadership for ASCO University®. Dr. Haller, who served as Editor-in-Chief of the Journal of Clinical Oncology from 2001-2011, believes his experience in the sphere of academic journals will translate nicely to his role and work with the Editorial Board for ASCO University. Dr. Haller explains, “We want to stay ahead of the curve in terms of learning modalities and continue to grow in areas such as mobile apps to provide different opportunities for lifelong learning.”  Dr. Haller is joined by a group of seven Associate Editors: Aditya Bardia, MD, of Massachusetts General Hospital; Quyen Chu, MD, of Louisiana State University Health Sciences Center; Jill Gilbert, MD, of Vanderbilt University; David Graham, MD, of Carle Clinic Association; Heather Hylton, PA-C, of Memorial Sloan-Kettering Cancer Center; Benjamin Levy, MD, Beth Israel Hospital; and Bhoomi Mehrotra, MD of St. Francis Hospital.  What is the purpose of the Editorial Board?  For the past five years, oncology professionals at every career level have found thorough, accurate, and timely educational content in a convenient online format on ASCO University. As the content has expanded exponentially, ASCO has seen a clear need for dedicated member leadership and oversight of ASCO University.  The purpose of the Editorial Board is to ensure that the portfolio of educational products and services provided through ASCO University achieves its purpose of being a high-quality, comprehensive, educational resource that supports the lifelong learning needs of oncology professionals. Why did you decide to lead this group? “As a member and an oncologist, I understand the educational needs that we all share. I plan to find out what the oncology community needs and focus on topics and formats for this audience.” As a result, it is important, Dr. Haller noted, that members guide the growth of ASCO University. The Editorial Board encourages users to provide feedback and suggestions based on the current ASCO University content by submitting an email to university@asco.org. As ASCO’s eLearning center, ASCO University is designed to serve as the online educational home for oncology care professionals. It encourages lifelong learning by offering practice resources and educational opportunities to those within all subspecialties of oncology. Some of the featured content available on ASCO University includes:ASCO Tumor Boards: Monthly multidisciplinary presentations that explore evidence relating to issues in case scenario.Oncology Literature Reviews: Quarterly summaries of key papers published in JCO and other major oncology journals.Focus Under Forty: Courses exploring unique issues and challenges of patients, ages 15-39, with cancer.ASCO-SEP Third Edition®: ASCO-SEP is a comprehensive oncology learning resource that can be used for self-study.Exam Preparation: Individual self-assessment courses each including between 20-30 questions, which provide additional sources of practice questions on some of the following topics: Clinical Pharmacology, Biostatistics, Palliative Care, Gynecologic Cancers, GI Cancers, Leukemia, Molecular Oncology, Cancer Genetics, Head and Neck Cancers, and CNS Tumors.Maintenance of Certification - MOC: Courses providing opportunity to earn ABIM points for Parts II and IV MOC.Flashcards: Digital flashcards designed to assist those newer to the oncology field study key topics.Daily Medical Education: Using mobile technologies, these courses push two daily self-assessment questions to a subscriber’s email where users can then quickly fill a moment during their day with oncology learning.  payten.carroll Fri, 17 May 2013 17:00:14 GMT f1397696-738c-4295-afcd-943feb885714:3536 http://connection.asco.org/Magazine/Article/ID/3535/ASCOs-Curriculum-for-Advanced-Practice-Providers-ACAPP-2013.aspx#Comments 0 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=141&ModuleID=498&ArticleID=3535 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=3535&PortalID=0&TabID=141 http://connection.asco.org/Magazine/Article/ID/3535/ASCOs-Curriculum-for-Advanced-Practice-Providers-ACAPP-2013.aspx In response to the need for educational resources that target Advanced Practice Providers (APPs) that are new to an oncology practice, ASCO University® has designed a curriculum that practices can use to assist with orientation of their new employees. A Planning Group, led by Katie Beekman, MD, member of the Integrated Media and Technology Committee and the Workforce Advisory Group, has provided oversight for curriculum development for this initiative. Dr. Beekman is joined by five additional planning group members: Dean Bajorin, MD; Memorial Sloan Kettering Cancer Center; Dan Hayes, MD; Maine Center for Cancer Med; Barbara McAneny, MD; New Mexico Oncology Hematology Consultants; Todd Pickard, MMSc, PA-C; MD Anderson Cancer Center; Cindy Tofthagen, PhD, ARNP; University of South Florida.  Dr. Beekman explains that “The ASCO University® Curriculum for Advanced Practice Providers stemmed from recognition by multiple groups within ASCO that APPs are an important and growing part of the oncology care team. Many ASCO members have noted that training APPs in oncology is one barrier for practices in utilizing an APP in their practice. We felt that a coordinated effort by ASCO University® to present educational material relevant for the practice and the APP would be welcomed. We are very excited to have this now available and hope that practices take advantage of it.”  Since the individual needs for each practice may greatly vary, a Core Curriculum, containing Basic and Premium levels of content, and individual Tumor-Focused Curricula are available. A post-assessment is included in the Core Curriculum Basic Package, as well as for each of the Tumor Packages. To document participation, a Certificate of Completion from ASCO University® is available for all courses.  A majority of the courses also include the potential to earn CME credit. Oncology Practices may purchase activation codes for use by their employees. Individual APPs may also purchase the curriculum. Enrollment requirements include:ASCO.org account for members or guest account for non-membersDocumentation of NP or PA certification, including current certification numberDownloadable registration form available online – To register, please visit ASCO University® at http://university.asco.org/app. The table provided below includes a detailed list of course content that is available for purchase on ASCO University®.  For more information, please send an e-mail to ASCO University® at university@asco.org. payten.carroll Fri, 17 May 2013 16:45:56 GMT f1397696-738c-4295-afcd-943feb885714:3535 http://connection.asco.org/Magazine/Article/ID/3534/New-Directions-for-the-Educational-Book.aspx#Comments 0 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=141&ModuleID=498&ArticleID=3534 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=3534&PortalID=0&TabID=141 http://connection.asco.org/Magazine/Article/ID/3534/New-Directions-for-the-Educational-Book.aspx Don Dizon, MD, FACP, Immediate Past Chair of the Integrated Media & Technology Committee is an academic medical oncologist specializing in breast and gynecologic malignancies as well as sexuality and intimacy issues for cancer survivors at Massachusetts General Hospital, Gillette Center for Women’s Cancers. Dr. Dizon has recently been appointed as Editor of the ASCO Educational Book and sat down to share his recent thoughts about his appointment for what’s new in 2013. What’s new in 2013 for the Educational Book? The ASCO Educational Book, which is published in conjunction with the ASCO Annual Meeting, publishes peer reviewed manuscripts by Meeting faculty on a variety of topics related to cancer, highlighting both standards of care and therapeutic possibilities. The ASCO Educational Book has recently been accepted for indexing in the National Library of Medicine’s MEDLINE database, making all ASCO Educational Book articles citable and discoverable via PubMed. What are your ideas for expanding its scope during your term as editor? Dr. Dizon explains, “Now that the ASCO Educational Book has been accepted by the National Library of Medicine, this provides an amazing opportunity to expand the scope of this resource for all oncology care providers from fellows to attending physicians.” Articles from the 2013 ASCO Educational Book and related materials will form the basis of developing an Ed Book Essentials course that will be hosted on ASCO University. This online course will be available in July and will focus on key articles related to treatment of the newly diagnosed patients with early breast cancer and bridging technological advances with clinical practice. Additionally, a new Flashcard course will be developed focusing on important concepts from key articles related to the Pediatric Oncology track.  Why is this new initiative being implemented? By using an online format, these new courses will provide a modern look for the ASCO Educational Book and provide an opportunity to include lifelong learning tools that are accessible to larger audience which is especially important given ASCO’s global reach. Further, this course complements the ASCO Annual Meeting by providing content that is available in an easily accessible learning format. payten.carroll Fri, 17 May 2013 16:40:00 GMT f1397696-738c-4295-afcd-943feb885714:3534 http://connection.asco.org/Magazine/Article/ID/3533/Learn-About-the-New-2014-MOC-Changes-and-How-They-Will-Impact-You.aspx#Comments 0 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=141&ModuleID=498&ArticleID=3533 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=3533&PortalID=0&TabID=141 http://connection.asco.org/Magazine/Article/ID/3533/Learn-About-the-New-2014-MOC-Changes-and-How-They-Will-Impact-You.aspx Early in 2014, the American Board of Internal Medicine (ABIM) will implement changes in its Maintenance of Certification (MOC) program. The American Board of Medical Specialties (ABMS), of which ABIM is a member, is requiring more frequent participation in MOC of all Board Certified physicians.  ABIM and ABMS, along with other external health organizations and the general public, believe that a more continuous MOC program helps you keep pace with the changes in the science of medicine and assessment.New MOC requirements beginning January 2014:Complete an ABIM MOC program activity to earn MOC points every two years, and earn 100 points every five years. Items to note:Points earned every two years will count toward the five-year requirement.Physicians may choose to complete any MOC activity to meet the two-year requirement.Physicians will also have to complete a patient survey and a patient safety module by December 31, 2018, and every five years thereafter.Physicians will be required to pass a secure exam once every 10 years and, beginning in 2014, will earn MOC points for their first MOC exam attempt.Physicians in fellowship training will earn 20 MOC points for each year of training they successfully complete.ABIM has created a website to provide you with more detailed information on the changing requirements, which is available at http://moc2014.abim.org. Additionally, ASCO would like to help members navigate the new MOC requirements and provide information on products and resources we have available to assist with maintaining their certificates. Visit http://university.asco.org/maintenance-certification to learn more about ASCO’s MOC approved products. payten.carroll Fri, 17 May 2013 16:32:34 GMT f1397696-738c-4295-afcd-943feb885714:3533 http://connection.asco.org/Magazine/Article/ID/3528/Help-ASCO-Choose-Incoming-Leadership-by-Nominating-a-Colleague-for-2014-ASCO-Election.aspx#Comments 0 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=141&ModuleID=498&ArticleID=3528 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=3528&PortalID=0&TabID=141 http://connection.asco.org/Magazine/Article/ID/3528/Help-ASCO-Choose-Incoming-Leadership-by-Nominating-a-Colleague-for-2014-ASCO-Election.aspx Do you know someone who would make a good ASCO President, Board member, or Nominating Committee member? ASCO Election season is here and we are asking all members to help the Society choose its incoming leadership, including the incoming ASCO President and members of the ASCO Board of Directors and Nominating Committee, by participating in the nomination process. Nominations will be accepted until June 6; self-nominations are welcome. The open positions are:President-ElectBoard of DirectorsOne Community OncologistOne International OncologistOne Radiation OncologistOne Undesignated Specialty OncologistNominating Committee: Two Undesignated Specialty Oncologists Nominations can be submitted at nominations.asco.org. You will need your ASCO.org username and password to make a nomination. Questions, including how to obtain your ASCO.org username and password, can be directed to ascoelection@asco.org or (571) 483-1316. payten.carroll Tue, 07 May 2013 21:39:40 GMT f1397696-738c-4295-afcd-943feb885714:3528 http://connection.asco.org/Magazine/Article/ID/3525/Dr-Robert-S-Miller-Appointed-Editor-in-Chief-of-ASCOs-Patient-Information-Website-CancerNet.aspx#Comments 0 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=141&ModuleID=498&ArticleID=3525 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=3525&PortalID=0&TabID=141 http://connection.asco.org/Magazine/Article/ID/3525/Dr-Robert-S-Miller-Appointed-Editor-in-Chief-of-ASCOs-Patient-Information-Website-CancerNet.aspx Robert S. Miller, MD, FACP, a medical oncologist and recognized authority in breast cancer, survivorship care, and consumer health informatics, has been appointed Editor-in-Chief of ASCO’s patient information website, Cancer.Net. He will assume this role at the 2013 ASCO Annual Meeting in Chicago on June 1, and he succeeds Diane Blum, MSW, Chief Executive Officer for the Lymphoma Research Foundation (LRF), who served as Editor-in-Chief for 10 years. “I have been fortunate to serve as an Associate Editor of Cancer.Net for the past several years, and am deeply honored to be taking on this new role,” said Dr. Miller. “Cancer.Net is a cornerstone of ASCO’s patient advocacy and communication strategies, and I certainly want to see all of the resources the site offers flourish and reach an even wider audience.” “Dr. Miller has been a long-term advocate of measures that enhance cancer care, and as Editor-in-Chief of Cancer.Net, he will further that commitment by lending his vision to a resource that people with cancer and their loved ones trust to provide timely, oncologist-approved information,” said ASCO President Sandra M. Swain, MD, FACP. “We are eager to embrace his vision for Cancer.Net, and to advance ASCO's mission of empowering those with cancer by providing resources that help them make informed decisions and advocate for their best care.” A key component of Dr. Miller’s vision for Cancer.Net includes enhancing the site’s interactivity. Through expanding Cancer.Net’ social media capabilities—including hosting tweetchats and incorporating more guest blog posts by those with cancer—he aims to create more opportunities for dialogue between well-known, prominent cancer researchers and people with the disease. Currently, Dr. Miller is an Assistant Professor of Oncology at the Johns Hopkins University School of Medicine, and Clinical Associate of the Breast Cancer Program and Oncology Medical Information Officer at the Sidney Kimmel Comprehensive Cancer Center. He earned his medical degree from the Medical College of Virginia School of Medicine, completed a residency in Internal Medicine at the University of California at San Francisco, a fellowship in Medical Oncology at Stanford University School of Medicine, and received his graduate certificate in biomedical informatics at Oregon Health and Science University. Dr. Miller has been an active ASCO member and volunteer since 1992. He currently serves on the Health Information Technology Workgroup, the Cancer Education Committee, and the editorial boards of Cancer.Net and the Journal of Oncology Practice (JOP), where he is a consultant editor and producer of the JOP podcast series. He is chair of the ASCO Integrated Media and Technology Committee and an active ASCOConnection.org blogger. Previously, he was a member of the ASCO Board of Directors. For his dedication to the Society, ASCO awarded Dr. Miller a Fellow of the American Society of Clinical Oncology (FASCO) Award in 2011. He is a past recipient of an ASCO Travel Award from the Conquer Cancer Foundation. Dr. Miller is also a member of the American College of Physicians and the American Medical Informatics Association. He is a former member of the Oncology Workgroup of the Certification Commission for Health Information Technology (CCHIT). ascoadmin Wed, 01 May 2013 13:16:33 GMT f1397696-738c-4295-afcd-943feb885714:3525 http://connection.asco.org/Magazine/Article/ID/3517/Foundation-Events-Slated-for-the-2013-ASCO-Annual-Meeting.aspx#Comments 0 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=141&ModuleID=498&ArticleID=3517 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=3517&PortalID=0&TabID=141 http://connection.asco.org/Magazine/Article/ID/3517/Foundation-Events-Slated-for-the-2013-ASCO-Annual-Meeting.aspx The Foundation looks forward to hosting a variety of events at the ASCO Annual Meeting. Conquer Cancer Foundation Grants and Awards Ceremony and Networking Reception The Conquer Cancer Foundation will be hosting an awards ceremony and networking reception on June 2, 2013, 5:00 PM–7:00 PM, at the Hyatt McCormick Place Regency Ballroom. All past and current recipients of Conquer Cancer Foundation grants and awards will be invited to join the Foundation for a cocktail and hors d'oeuvres reception that will honor the 2013 recipients and celebrate the 30th anniversary of the Conquer Cancer Foundation Grants and Awards Program. Attendees will also have the opportunity to network with members of the Grants Selection Committee and its review subcommittees, members of ASCO and Foundation leadership, supporters of the Foundation, and fellow grant and award recipients. Grant Writing Workshop Charles Rudin, MD, and Eric Small, MD, are Co-Chairs of the 2013 Grant Writing Workshop, which will be held on Friday, May 31, 1:00 PM–5:00 PM in McCormick Place, Room S103. Presentations during the first part of the workshop will include such topics as choosing a mentor and obtaining letters of support, an overview of the Foundation grants program, developing a hypothesis and stating aims, and general tips for grant-writing best practices. There will also be a mock study session in which presenters will review, critique, and score a grant application, which will in turn be followed by small-group discussions. View presentations from the 2012 Grant Writing Workshop online at conquercancerfoundation.org, under the "Cancer Professionals" section. This is not a ticketed session, and anyone attending the ASCO Annual Meeting is welcome to participate. ePassport Program The Foundation is excited to continue its ePassport to the World of Oncology Program this year. Attendees who collect six text codes from participating exhibitors in the Oncology Professionals Hall will be entered to win one of a variety of prizes: Free registration at the 2014 ASCO Annual MeetingA five-night stay in a downtown Chicago hotel during the 2014 ASCO Annual MeetingOne year of access to the Oncology Slide Library A list of participating exhibitors will be included in the online and printed directory, the 2013 ASCO Annual Meeting iPlanner, and Interactive Locator Maps onsite. Attendees can access the ePassport using the iPlanner app on their smartphones or tablets. Winners will be notified via email following the 2013 Annual Meeting. Visit the Passport Booth outside the Oncology Professionals Hall for more details and a small giveaway (while supplies last, one per person). Donor Lounge All Conquer Cancer Foundation donors are invited to visit the Donor Lounge at the 2013 ASCO Annual Meeting (Room S401). Find a quiet place to relax, network with colleagues, enjoy light refreshments, and learn more about the Foundation's activities. Make a donation online at conquercancerfoundation.org/donate, or visit the Donor Lounge during the Annual Meeting to donate in person. Daily Planner Upon arrival at the ASCO Annual Meeting, attendees should be sure to pick up their copy of the Conquer Cancer Foundation's Daily Planner. The Daily Planner gives attendees a place to map out their personal schedules, including sessions they are most interested in attending. The Daily Planner also contains space for notes, as well as information about the Foundation and its programs. Daily Planners can be picked up at Registration—North Building, Level 2, Hall C or at the satellite eTote pickup, South Building, Level 1, Gate 3. Conquer Cancer Foundation Celebration Dinner This year, the Foundation will host the Second Annual Conquer Cancer Foundation Celebration Dinner on Saturday, June 1. Guests will gather to celebrate the international programs the Foundation is able to support as a result of the generous contributions of its donors. Entry to the event is by invitation only. ascoadmin Sun, 21 Apr 2013 00:14:18 GMT f1397696-738c-4295-afcd-943feb885714:3517 http://connection.asco.org/Magazine/Article/ID/3516/The-Conquer-Cancer-Foundations-Endowed-Young-Investigator-Awards.aspx#Comments 0 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=141&ModuleID=498&ArticleID=3516 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=3516&PortalID=0&TabID=141 http://connection.asco.org/Magazine/Article/ID/3516/The-Conquer-Cancer-Foundations-Endowed-Young-Investigator-Awards.aspx Fulfilling the promise of today's remarkable advances relies on funding for research projects and support for investigators. As a charitable organization, the Conquer Cancer Foundation of the American Society of Clinical Oncology supports progress by funding cancer researchers at all stages of their careers—enabling oncology's best and brightest to pursue promising research. The Conquer Cancer Foundation Grants and Awards Program is one of the largest grants programs among professional societies, with more than $78 million in funding awarded since its inception. The first Young Investigator Award (YIA) was awarded in 1984, and in the 30 years since, nearly $29 million in YIAs has been awarded. As the Grants and Awards Program has expanded, it has increasingly reflected the commitment of both the Foundation and ASCO to support research in all oncology subspecialties and emerging disciplines, such as cancer prevention, survivorship and quality of life, geriatric oncology, and fertility preservation. The YIA is a one-year, $50,000 research grant designed to encourage and promote quality research in clinical oncology. The YIA provides funding to promising physician investigators during the transition from fellowship programs to faculty appointments. Applicants must be physicians (MD, DO, or international equivalent) currently within the last two years of their final subspecialty training at an academic medical institution at the time of grant submission, and should be planning an investigative career in clinical oncology. Permanent revenue streamsIn an effort to ensure long-term support of cancer research, the endowment of research grants such as the YIA is imperative. An endowment fund, once fully funded, will provide a permanent revenue stream for its intended designation. In the case of an endowed YIA, the endowment will provide enough funding to award one YIA each and every year in perpetuity.The Foundation's first endowed YIA honors the personal passion of its namesake. In 2012, the Breast Cancer Research Foundation established the Conquer Cancer Foundation Young Investigator Award in memory of Evelyn H. Lauder. Ms. Lauder spent her life dedicated to preventing breast cancer and finding a cure. Beginning with the 2013 ASCO Annual Meeting, this YIA will be awarded annually to a promising young physician-scientist who is performing clinical or translational breast cancer research. Support of an endowed YIA can be established in many ways and can be payable over a period of time, as necessary. This support creates a permanently named award. In 2013, support of a single YIA is $60,000. For more information about making a charitable gift to establish a Young Investigator Award, contact Sarah Sasman Jacoby, Major Gift Officer at the Conquer Cancer Foundation, at sarah.jacoby@conquercancerfoundation.org. For more information about applying for a YIA, please visit the Conquer Cancer Foundation's website at conquercancerfoundation.org/yia. ascoadmin Sat, 20 Apr 2013 23:44:38 GMT f1397696-738c-4295-afcd-943feb885714:3516 http://connection.asco.org/Magazine/Article/ID/3515/May-2013-Spotlight-on-Education-Meetings.aspx#Comments 0 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=141&ModuleID=498&ArticleID=3515 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=3515&PortalID=0&TabID=141 http://connection.asco.org/Magazine/Article/ID/3515/May-2013-Spotlight-on-Education-Meetings.aspx Upcoming International Meetings International Clinical Trials WorkshopJune 12-13, 2013; Opatija, Croatia; Croatian Society of Oncology June 14-16, 2013; St. Petersburg, Russia; Russian Society of Clinical Oncology (RUSSCO) Multidisciplinary Cancer Management Courses July 26-28, 2013; La Paz, Bolivia; Oncovida Palliative Care Workshop July 1-5, 2013; Accra, Ghana; Africa Oxford Cancer Foundation (AfrOx)Visit asco.org/international for details. Unable to Attend the Annual Meeting in Chicago? Join us for one of the 2013 Best of ASCO® Meetings Best of ASCO Chicago August 9-10, 2013 Best of ASCO Los Angeles August 16-17, 2013 Best of ASCO Boston August 23-24, 2013 Housing and Early Registration Deadline: July 10, 2013, at 11:59 PM (EDT) Visit boa.asco.org for more details, including the agenda, abstracts, and confirmed faculty. Upcoming Best of ASCO® International Meetings June 13-15, 2013, Opatija, Croatia June 14, 2013, Toronto, Canada June 14-15, 2013, Frankfurt, Germany June 21-22, 2013, Beirut, Lebanon June 27-29, Cancun, Mexico June 28-30, 2013, Mumbai, India June 2013, Paris, France July 6-7, 2013, Yokohama, Japan July 26-27, 2013, Panama July 26-27, 2013, Cuenca, Ecuador August 2-3, 2013, Porto Alegre, Brazil August 3, 2013, Melbourne, Australia August 16-17, 2013, Salvador, Brazil August 23-25, 2013, Barbados September 1, 2013, Lima, Peru September 17-22, 2013, Mexico City, Mexico September 28-29, 2013, Baghdad, Iraq Last week of September 2013, Cairo, Egypt September 2013, Eretria, Greece September 2013, Dammam, Saudi Arabia September/October 2013, Bratislava, Slovakia Best of ASCO® International will also be held in the following locations (dates to be determined): Turkey, Singapore, North Maghreb, China. Visit boa.asco.org/officially-licensed-best-asco-meetings for more information. Mark Your Calendars for Important Symposia Dates2013 Breast Cancer SymposiumSeptember 7-9, 2013; San Francisco, California; breastcasym.orgThe 2013 Breast Cancer Symposium provides multidisciplinary perspectives on clinical management. It also contains an exciting new track of complimentary ticketed sessions designed exclusively for fellows, residents, and junior faculty.Abstract Submission Deadline: May 7, 2013 at 11:59 PM (EDT)Housing and Early Registration Deadline: July 31, 2013, at 11:59 PM (EDT)Markers in Cancer: A Joint Meeting by ASCO, EORTC, and NCI November 7-9, 2013; Brussels, Belgium; markersincancer.org Diagnostic Development Tutorial: November 5-7, 2013; Brussels, Belgium Registration Opens: May 7, 2013 Abstract Submission Deadline: June 20, 2013, at 10:00 AM (CEST) ASCO's Quality Care Symposium November 1-2, 2013; San Diego, California; quality.asco.org Abstract Submitter, Housing, and Registration Open: Mid-May 2013 Abstract Submission Deadline: July 2, 2013, at 11:59 PM (EDT) ascoadmin Sat, 20 Apr 2013 23:20:30 GMT f1397696-738c-4295-afcd-943feb885714:3515 http://connection.asco.org/Magazine/Article/ID/3513/ASCO-Universitys-New-Curriculum-for-Advanced-Practice-Providers.aspx#Comments 0 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=141&ModuleID=498&ArticleID=3513 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=3513&PortalID=0&TabID=141 http://connection.asco.org/Magazine/Article/ID/3513/ASCO-Universitys-New-Curriculum-for-Advanced-Practice-Providers.aspx Table 1. 2013 Curriculum for Advanced Practice Providers Core Curriculum—Basic Package Team-Based Care in Oncology Practice Communicating Prognosis Cancer Care for Older Patients Cancer Care for Adolescents and Young Adults Chemotherapy Safety Standards Grading and Staging of Tumors Overview of Anticancer Therapies, Spring 2013 Chemotherapy-Based Pharmacology, Spring 2013 Wound Healing after Radiation Therapy, Spring 2013 What It Costs to Deliver Care Who Pays for Health Care Medical Liability Genetic Testing Challenging Tumor Cases (Palliative Care) Chemotherapy-Induced Nausea and Vomiting Cancer Pain Delirium and Depression Palliative Radiation Cancer-Related Fatigue Cultural Competence for Cancer Caregivers, Fall 2013 Survivorship ASCO Flashcards: Oncology Terms ASCO Flashcards: Symptom Management ASCO Flashcards: Cancer Drug Toxicities, Spring 2013 ASCO Flashcards: Billing and Coding, Fall 2013   Core Curriculum—Premium Package ASCO-SEP 3rd Edition (eBook, Online Question Bank, Flashcards)   Tumor-Focused Supplemental Packages: Breast Cancer Gastrointestinal Cancers Genitourinary Cancers Lung Cancer Hematologic Malignancies To meet the demand for team-based care and address the growing shortage of health care workers, many oncology practices are hiring an increasing number of Advanced Practice Providers (APPs). Consequently, these practices have expressed a need for training materials for their new hires, and in response, ASCO University® has recently begun offering a new curriculum: ASCO's Curriculum for Advanced Practice Providers (ACAPP™). ACAPP offers a range of options for Advanced Practice Providers with varying levels of experience. The Core Curriculum, targeted for APPs who are new to an oncology practice, is offered as a Basic or Premium package, which includes ASCO-SEP®, 3rd edition. Tumor-Focused Curricula are available for more experienced Advanced Practice Providers who want to increase their knowledge of a specific topic. Tumor-Focused Curricula include tracks on breast cancer, gastrointestinal cancers, genitourinary cancers, lung cancer, and hematologic malignancies. Details about the specific package choices can be seen in Table 1. Kathleen Beekman, MD, a member of the Integrated Media and Technology Committee and the Workforce Advisory Group, led a planning team that developed the curriculum. "The ASCO University curriculum for Advanced Practice Providers stemmed from a recognition by multiple groups within ASCO that Advanced Practice Providers are an important and growing part of the oncology care team," said Dr. Beekman. "Many ASCO members have noted that training APPs in oncology is one barrier for practices in utilizing them in their practice. We felt that a coordinated effort by ASCO University to present educational material relevant for the practice and staff would be welcomed. We are very excited to have this now available and hope that practices take advantage of it." The members of the full planning committee, Kathleen Beekman, MD; Dean Bajorin, MD; Daniel Hayes, MD; Barbara McAneny, MD; Todd Pickard, MMSc, PA-C; and Cindy Tofthagen, PhD, ARNP, brought a variety of backgrounds to the planning process and chose topic areas based on what is most often seen in practice. "The workforce study shows that there will not be enough oncologists to see all the patients who need us, so we have been hiring APPs; however, we find ourselves doing on-the-job training, which has not been optimal, as we have not found training programs that meet the needs of APPs," said Dr. McAneny. "ASCO heard the need and has created a program which will be a great resource. We will use this program to bring our APPs the education they need to help them help our patients." Oncology practices may purchase activation codes for their employees, or individual APPs may also purchase the curriculum. To help gauge comprehension, a post-assessment is included in both packages. In addition, all courses offer a Certificate of Completion from ASCO University to document participation. ascoadmin Fri, 19 Apr 2013 03:16:20 GMT f1397696-738c-4295-afcd-943feb885714:3513 http://connection.asco.org/Magazine/Article/ID/3512/ASCO-Develops-New-Physician-Payment-Reform-Webpage-and-Four-Part-Educational-Series.aspx#Comments 0 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=141&ModuleID=498&ArticleID=3512 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=3512&PortalID=0&TabID=141 http://connection.asco.org/Magazine/Article/ID/3512/ASCO-Develops-New-Physician-Payment-Reform-Webpage-and-Four-Part-Educational-Series.aspx To help keep its members and the cancer community apprised and educated on the issue of payment reform, ASCO has developed a payment reform webpage and issued an ASCO in Action educational series. This four-part series is designed to help ASCO members better understand the complex issue of physician payment reform: Part 1 provides an overview of the issue; Part 2 discusses the Sustainable Growth Rate formula; Part 3 provides details on the current buy-and-bill system of reimbursing for oncology drugs; and Part 4 discusses payment reform options being considered as alternatives to the current fee-for-service system. To read the series, go to ASCO’s physician payment reform page at asco.org/paymentreform. payten.carroll Thu, 18 Apr 2013 18:53:02 GMT f1397696-738c-4295-afcd-943feb885714:3512 http://connection.asco.org/Magazine/Article/ID/3511/Affordable-Care-Act-Sunshine-Rule-CMS-Issues-Final-Rule.aspx#Comments 0 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=141&ModuleID=498&ArticleID=3511 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=3511&PortalID=0&TabID=141 http://connection.asco.org/Magazine/Article/ID/3511/Affordable-Care-Act-Sunshine-Rule-CMS-Issues-Final-Rule.aspx The Centers for Medicare and Medicaid Services (CMS) recently announced a final rule implementing Section 6002 of the Affordable Care Act (the “National Physician Payment Transparency Program: Open Payments”). The final rule, commonly called the “Sunshine” rule, will make information publicly available about payments or other transfers of value from applicable manufacturers to physicians and teaching hospitals (“covered recipients”), and about physician (or immediate family members of a physician) ownership or investment interests in applicable manufacturers and group purchasing organizations (GPOs).Under this rule, applicable manufacturers must report annually to the Health and Human Services Secretary all payments or transfers of value (including gifts, consulting fees, research activities, speaking fees, meals, and travel) from applicable manufacturers to covered recipients. Applicable manufacturers and GPOs must also report ownership and investment interests held by physicians (or their immediate family members) in such entities. This reported information will be posted on a publicly available website.Key Definitions:Applicable manufacturers—entities operating in the United States that either produce or prepare at least one drug, device, biologic, or medical supply that is covered by Medicare, Medicaid, or Children’s Health Insurance Program (CHIP), and entities under common ownership with applicable manufacturers.Applicable GPOs—entities operating in the United States that purchase, arrange for, or negotiate the purchase of covered drugs, devices, biologics, or medical supplies for a group of individuals or entities.Teaching hospital—any hospital that receives indirect medical education, direct graduate medical education, or psychiatric hospital Insurance Medical Exam (IME).The law does not require applicable manufacturers or GPOs to report ownership or investment interests held by teaching hospitals.Data collection will begin on August 1, 2013. Applicable manufacturers and GPOs will report data for August-December 2013 to CMS by March 31, 2014. CMS will release the data publicly by September 30, 2014. For additional details, please see the final rule atfederalregister.gov/public-inspection. payten.carroll Thu, 18 Apr 2013 17:39:01 GMT f1397696-738c-4295-afcd-943feb885714:3511 http://connection.asco.org/Magazine/Article/ID/3503/ASCO-FDA-CoHost-Clinical-Trials-Workshops.aspx#Comments 0 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=141&ModuleID=498&ArticleID=3503 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=3503&PortalID=0&TabID=141 http://connection.asco.org/Magazine/Article/ID/3503/ASCO-FDA-CoHost-Clinical-Trials-Workshops.aspx In February and March, ASCO co-hosted several workshops with the FDA to discuss important topics in clinical trials: "Innovations in Breast Cancer Drug Development—Neoadjuvant Breast Cancer" included topics on how neoadjuvant trials can expedite drug development; the Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC) meta-analysis results; and the draft "FDA Guidance for Industry: Use of Pathologic Complete Response in Neoadjuvant Treatment of High-Risk Early Stage Breast Cancer as an Endpoint to Support Accelerated Approval." ASCO President Sandra M. Swain, MD, FACP, and the FDA's Patricia Cortazar, MD, served as Co-Chairs of the workshop. Two workshops on minimal residual disease detection as a prognostic biomarker to that of an efficacy/response biomarker in evaluating new drugs for the treatment of chronic lymphocytic leukemia and acute myeloid leukemia provided a venue for an in-depth discussion of potential surrogate endpoints for trials intended to support the approval of new drugs or biologics.Visit fda.gov/drugs/newsevents for more information. ascoadmin Wed, 17 Apr 2013 18:36:24 GMT f1397696-738c-4295-afcd-943feb885714:3503 http://connection.asco.org/Magazine/Article/ID/3502/NCI-Clinical-Trials-System-Restructuring-Threatened-by-Budget-Cuts.aspx#Comments 0 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=141&ModuleID=498&ArticleID=3502 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=3502&PortalID=0&TabID=141 http://connection.asco.org/Magazine/Article/ID/3502/NCI-Clinical-Trials-System-Restructuring-Threatened-by-Budget-Cuts.aspx As the National Cancer Institute (NCI) finalizes the restructuring of its Cooperative Group clinical trials system, budget cuts threaten the progress made and important revitalization efforts still needed, according to speakers at a February 2013 workshop hosted by ASCO and the Institute of Medicine's (IOM's) National Cancer Policy Forum. The recent federal government sequester—which went into effect March 1—cut 5% of the National Institutes of Health's budget, of which NCI is a part. NCI baseline funding for its clinical trial system currently stands at $152 million annually, but the institute had committed to increase its funding to $178 million as part of the effort to modernize and strengthen the system. If the budget cuts are across the board, this funding could be at risk. Fewer, but more complicated trials expected NCI is finalizing the consolidation of 10 adult clinical trials cooperative groups into four—as recommended by a 2010 IOM report—with the Children's Oncology Group remaining on its own. The new system will be known as the National Clinical Trials Network (NCTN). Patient accrual to Cooperative Group trials has decreased from a high of about 28,000 to 23,000 currently, and NCI envisions NCTN as running at about 20,000 patient accruals per year eventually, said ASCO member Robert L. Comis, MD, Co-Chair, ECOG-ACRIN Cancer Research Group, and President and Chairman, Coalition of Cancer Cooperative Groups. The system would run fewer, but more complicated trials, including fewer large phase III studies and more phase II studies. Also, NCI plans to restructure its Community Clinical Oncology Program—which has accrued 250,000 patients to NCI trials since its inception in 1983—are being viewed "with some trepidation" in the community, said ASCO Board member Stephen Grubbs, MD, of the Helen F. Graham Cancer Center and Christiana Care CCOP. "We will have to learn how to accrue patients to phase II trials, but we can do it," he said. In addition, the NCI plan (as discussed at the workshop) involves community sites conducting cancer care delivery research, which is outside the current CCOP scope. The workshop, Implementing a National Cancer Clinical Trials System for the 21st Century, held February 11-12, in Washington, DC, was the second meeting ASCO co-sponsored to follow up on the recommendations of the 2010 IOM report, "A National Cancer Clinical Trials System for the 21st Century." Past ASCO Board of Directors member Monica Bertagnolli, MD, served as chair of the workshop planning committee. Dr. Bertagnolli is Chief, Division of Surgical Oncology, Brigham and Women's Hospital and Chair, Alliance for Clinical Trials in Oncology. ascoadmin Wed, 17 Apr 2013 18:30:18 GMT f1397696-738c-4295-afcd-943feb885714:3502 http://connection.asco.org/Magazine/Article/ID/3495/Explore-ASCOs-2012-Accomplishments-in-Annual-Report.aspx#Comments 0 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=141&ModuleID=498&ArticleID=3495 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=3495&PortalID=0&TabID=141 http://connection.asco.org/Magazine/Article/ID/3495/Explore-ASCOs-2012-Accomplishments-in-Annual-Report.aspx The 2012 ASCO Annual Report is available online as an enhanced PDF. Learn about the Society's ongoing programs and new initiatives from the past year, including a continued focus on high-quality, high-value cancer care; highlights from educational meetings; and advocacy and policy efforts. The report also includes information on ASCO's revenues and expenses from 2012, membership demographics, leadership information, and an acknowledgment of donors to the Conquer Cancer Foundation of the American Society of Clinical Oncology.  Embedded video and hyperlinks within this electronic publication mean that more detailed information about ASCO programs, services, and resources is available at your fingertips. iPad users can access the 2012 Annual Report through ASCO's iLibrary app (free; member sign-in required). virginia.anderson Tue, 09 Apr 2013 19:37:59 GMT f1397696-738c-4295-afcd-943feb885714:3495 http://connection.asco.org/Magazine/Article/ID/3493/Video-Series-for-Young-Adults-with-Cancer.aspx#Comments 0 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=141&ModuleID=498&ArticleID=3493 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=3493&PortalID=0&TabID=141 http://connection.asco.org/Magazine/Article/ID/3493/Video-Series-for-Young-Adults-with-Cancer.aspx  ASCO Member Sonali Smith, MD, discusses fertility and cancer in the “Moving Forward” video series on Cancer.Net.April 2013: ASCO and the LIVESTRONG Foundation worked together to launch a video series designed for people diagnosed with cancer between ages 15 and 39. The series, “Moving Forward: Perspectives from Survivors and Doctors,” offers information on common challenges faced by young adults with cancer. Each topic in the series consists of two videos: one from ASCO that offers guidance from medical health care experts, and one from LIVESTRONG that provides views from young adult survivors on the same topic. The 12 video pairings in the series offer information on the fear of recurrence, fertility concerns, and medical-expenses tracking, body changes, dating and sexuality, diet and exercise, family and friends, fear of dying, health insurance, managing pain, school, and work.  Direct your patients to cancer.net/movingforward or Cancer.Net’s channel on YouTube (youtube.com/cancerdotnet). This video series was made possible by a grant from LIVESTRONG to the Conquer Cancer Foundation, which supports Cancer.Net. devon.carter Thu, 04 Apr 2013 14:30:10 GMT f1397696-738c-4295-afcd-943feb885714:3493 http://connection.asco.org/Magazine/Article/ID/3488/In-the-Journals.aspx#Comments 0 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=141&ModuleID=498&ArticleID=3488 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=3488&PortalID=0&TabID=141 http://connection.asco.org/Magazine/Article/ID/3488/In-the-Journals.aspx JCO SnapshotsResults from recent articles, personally selected by JCO Editor-in-Chief Stephen A. Cannistra, MD"Limited clinically useful information was derived from routine (bone marrow biopsy) BMB in newly diagnosed patients with (Hodgkin lymphoma) HL who were diagnosed in hematology centers with access to (positron emission tomography/computed tomography) PET/CT staging," according to the JCO article by El-Galaly, et al., published in the December 20, 2012, print issue. "Consequently, omission of BMB would not have influenced the treatment strategy for any of the patients analyzed in this study." The activity of cabozantinib in patients with castration-resistant prostate cancer (CRPC) in a phase II randomized discontinuation trial with an expansion cohort was evaluated by Smith, et al., in a JCO Rapid Communications article that published in the February 1, 2013, print issue. The authors found that "cabozantinib has clinical activity in men with CRPC, including reduction of soft tissue lesions, improvement in (progression-free survival) PFS, resolution of bone scans, and reductions in bone turnover markers, pain, and narcotic use."In an open-label, two-stage phase II study, researchers found that the selective, allosteric MEK1/MEK2 inhibitor trametinib (GSK1120212) was well tolerated in patients with metastatic BRAF-mutant melanoma, according to the JCO article by Kim, et al., that published in the February 1, 2013, print issue. Visit jco.ascopubs.org to access the full articles and podcasts.New Associate Editor Joins JCOJoel E. Tepper, MD, a radiation oncologist with expertise in gastrointestinal cancers, was named an Associate Editor of the Journal of Clinical Oncology (JCO). Dr. Tepper is the Hector McLean Distinguished Professor of Cancer Research at the Carolina Center of Cancer Nanotechnology Excellence at the University of North Carolina at Chapel Hill.March JOP Explores Updated ASCO/ONS Chemotherapy Administration Safety Standards GuidelineThe March 2013 issue of the Journal of Oncology Practice (JOP) features content built around the recently updated ASCO/Oncology Nursing Society (ONS) published standards for the safe use of parenteral chemotherapy.Originally published in 2009, the guideline focused on the outpatient setting, including issues of practitioner orders, preparation, and administration of medication. In 2011, the guideline was updated to include inpatient facilities. Most recently, the guideline was updated again to include newly identified recommendations on drug prescriptions and the necessity of ascertaining that prescriptions are filled; the importance of patient and family education regarding administration schedules; exception procedures; disposal of unused oral medication; and aspects of continuity of care across settings.In addition to the complete ASCO/ONS standards and 2013 guideline updates, JOP content includes:Perspective article by Monika K. Krzyzanowska, MD, from Princess Margaret Hospital, Toronto, Canada, titled, "Time to Get Serious about Improving the Safety of Oral Chemotherapy"Perspective article by Mary Gullatte, PhD, RN, ANP-BC, AOCN, FAAN, from the Oncology Nursing Society, on the ASCO/ONS collaborationOriginal Contribution by Terry R. Gilmore; Lisa Schulmeister, MN, RN, OCN; and Joseph O. Jacobson, MD, on ASCO's Quality Oncology Practice Initiative (QOPI®) certification program and how it relates to the ASCO/ONS Standards for Safe Chemotherapy Administration guideline.To read the full issue, visit jop.ascopubs.org.JCO Leading Reads – January– March 2013Impact of FOLFIRINOX Compared With Gemcitabine on Quality of Life in Patients With Metastatic Pancreatic Cancer: Results From the PRODIGE 4/ACCORD 11 Randomized Trial By Sophie Gourgou-Bourgade, et al. Bevacizumab in Stage II-III Colon Cancer: 5-Year Update of the National Surgical Adjuvant Breast and Bowel Project C-08 Trial by Carmen J. Allegra, et al.Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial by David C. Smith, et al.Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies by Ranjana H. Advani, et al.Randomized Phase III Placebo-Controlled Trial of Letrozole Plus Oral Temsirolimus As First-Line Endocrine Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer by Antonio C. Wolff, et al. devon.carter Thu, 28 Mar 2013 16:19:03 GMT f1397696-738c-4295-afcd-943feb885714:3488 http://connection.asco.org/Magazine/Article/ID/3482/For-Your-Patients.aspx#Comments 0 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=141&ModuleID=498&ArticleID=3482 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=3482&PortalID=0&TabID=141 http://connection.asco.org/Magazine/Article/ID/3482/For-Your-Patients.aspx Helping Patients Learn about Cancer Medication Storage and DisposalCancer.Net recently released several new resources to help patients and their caregivers learn about the importance of safely storing, handling, and disposing cancer medications, particularly those prescribed to relieve pain. Safe Storage and Disposal of Cancer Medications. This article, available at cancer.net/safestorage, provides patients with general tips on how to organize, store, and keep track of their medication. It addresses the special considerations needed for handling pain medications and oral chemotherapy. The article also covers the options for properly disposing cancer medications. This information has also been adapted into an audio podcast available at cancer.net/podcasts. ASCO Answers: Safe Storage and Disposal of Pain Medications. This fact sheet explains why patients may be prescribed pain medication, why it's important to know how to store the medication, and how to do so safely, as well as how patients should dispose of old or unused medication and used pain-relief patches. In addition, this fact sheet provides a list of questions patients may want to ask their doctors and a list of terms they may need to know. To order copies of this fact sheet to hand out in your office or waiting room, visit cancer.net/estore. In addition to the resources on medication storage and disposal, Cancer.Net provides several other related materials, including the following:•    A special article on the importance of taking medication correctly—available at cancer.net/features under the "Side Effects" option•    "Managing Side Effects: Pain"—available at cancer.net/sideeffects•    An ASCO Answers fact sheet on managing pain— available at cancer.net/factsheets •    A two-part special article on managing pain—available at cancer.net/features under the "Side Effects" option•    A video featuring ASCO experts and a cancer survivor on managing pain—available at cancer.net/movingforwardNew Editor-in-Chief Announced for Cancer.NetCancer.Net is proud to announce medical oncologist Robert S. Miller, MD, FACP, as the new Editor-in-Chief. Dr. Miller is an Assistant Professor of Oncology at the Johns Hopkins University School of Medicine and an Oncology Medical Information Officer at the Sidney Kimmel Comprehensive Cancer Center. He serves on the Editorial Board of the Journal of Oncology Practice and previously served as an Associate Editor for Cancer.Net. He is also a columnist on ASCOconnection.org. Look for a full interview with Dr. Miller in the ASCO Connection September Issue.ASCO patient education programs are supported by the Conquer Cancer Foundation of the American Society of Clinical Oncology. ascoadmin Mon, 25 Mar 2013 12:57:37 GMT f1397696-738c-4295-afcd-943feb885714:3482 http://connection.asco.org/Magazine/Article/ID/3469/ASCO-the-Society-of-Thoracic-Surgeons-Collaborate-on-New-Lung-Cancer-eLearning-Courses.aspx#Comments 0 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=141&ModuleID=498&ArticleID=3469 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=3469&PortalID=0&TabID=141 http://connection.asco.org/Magazine/Article/ID/3469/ASCO-the-Society-of-Thoracic-Surgeons-Collaborate-on-New-Lung-Cancer-eLearning-Courses.aspx As the field of thoracic oncology becomes increasingly more complex, multidisciplinary care involving the medical oncologist, radiation oncologist, and thoracic surgeon has become the rule, not the exception. Patients are no longer seeing just one physician for his or her cancer and thus forums like these are of paramount interest in educating physicians on this approach. Dr. Benjamin Levy, MD, Director of Thoracic Medical Oncology at Beth Israel Hospital in New York City and member of ASCO’s Integrated Media and Technology Committee indicates “the value of developing this online educational series between the Society of Thoracic Surgeons [STS] and ASCO is to provide an opportunity for medical and thoracic surgical oncologists, general surgeons, advanced thoracic surgical nurses, physician assistants, fellows, and other professionals to learn from renowned faculty who share similar perspectives in their approach for managing and treating lung cancer patients.” Dr. Yolonda Colson, MD, PhD, (Thoracic Surgeon) and member of the ASCO-STS Planning Group further explains: “Multidisciplinary educational programs create a format in which all viewpoints are shared. This in turn helps optimize medical decision making in more complex cases. The care of lung patients has, for better or worse, become more complicated, often requiring the intellectual input of all disciplines.” This three-part learning series developed between The STS and ASCO highlights and reinforces the approach of shared perspectives in managing lung cancer patients and improving care by providing the best options for each patient. Through case-based learning activities and detailed discussion, expert faculty including medical oncologists, radiation oncologists, and thoracic surgeons address overlapping educational needs between STS and ASCO which include such subjects as the role of surgery in patients with Stage IIIA cancer, the utility of adjuvant chemotherapy post resection, and surgery vs. radiation for early stage disease in medically high-risk patients. These three topics were felt to be some of the most interesting and innovative areas in thoracic oncology. For further information you can view the Lung Cancer (Early Stage): Screening & Management, Lung Cancer: Stereotactic Body Radiation Therapy vs. Surgical Resection, and Lung Cancer: Management of Stage IIIA Disease & Role of Surgery courses on ASCO University. Additional learning resources including select virtual meeting presentations and patient resources are also available to course participants.   ascoadmin Wed, 27 Feb 2013 13:24:17 GMT f1397696-738c-4295-afcd-943feb885714:3469 http://connection.asco.org/Magazine/Article/ID/3463/What-Your-Patients-Are-Reading-on-CancerNet.aspx#Comments 0 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=141&ModuleID=498&ArticleID=3463 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=3463&PortalID=0&TabID=141 http://connection.asco.org/Magazine/Article/ID/3463/What-Your-Patients-Are-Reading-on-CancerNet.aspx Guides to Cancer The wealth of information found in these detailed guides to 122 types of cancer make this section of the website the most popular (cancer.net/cancer). Recently, Cancer.Net users have been interested in learning more about thyroid cancer, adrenal gland tumor, sarcoma, and pancreatic cancer. Each of these guides divides the information into the following categories: Overview Treatment Statistics About Clinical Trials Medical Illustrations Coping with Side Effects Risk Factors After Treatment Signs and Symptoms Current Research Diagnosis Questions to Ask the Doctor Staging Advanced Cancer Care PlanningThis booklet, designed for patients with advanced cancer and their family and caregivers, is consistently the most downloaded booklet from Cancer.Net. It provides information on discussing options for care throughout the course of the illness and finding support. It is available for download in English and Spanish at cancer.net/advancedcancer, or professionally printed copies can be ordered at cancer.net/estore. SurvivorshipMany visitors are also interested in what happens after cancer treatment. Cancer.Net includes a detailed section on survivorship and provides information on next steps to take after treatment, common late effects of treatment, and rehabilitation. Downloadable cancer treatment summaries are also offered. Two of the top downloads in this section are the Breast Cancer Survivorship Treatment Plan and the Cancer Adjuvant Treatment Plan and Summary. In addition to this information, patients can access stories of survivorship and browse inspiring artwork from cancer survivors at cancer.net/survivorship. Top Five Cancer.Net Downloads1. Advanced Cancer Care Planning2. Breast Cancer Survivorship Treatment Plan3. Cancer Adjuvant Treatment Plan and Summary4. ASCO Answers: Pancreatic Cancer5. ASCO Answers: Breast CancerASCO patient education programs are supported by the Conquer Cancer Foundation. ascoadmin Wed, 27 Feb 2013 01:37:19 GMT f1397696-738c-4295-afcd-943feb885714:3463 http://connection.asco.org/Magazine/Article/ID/3462/March-2013-Spotlight-on-Education-Meetings.aspx#Comments 0 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=141&ModuleID=498&ArticleID=3462 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=3462&PortalID=0&TabID=141 http://connection.asco.org/Magazine/Article/ID/3462/March-2013-Spotlight-on-Education-Meetings.aspx Mark Your Calendars for Important Symposia DatesASCO/AACR Workshop: Methods in Clinical Cancer ResearchJuly 27-August 2, 2013; Vail, Colorado; vailworkshop.orgBreast Cancer SymposiumSaturday, September 7–Monday,September 9, 2013; San Francisco, California; breastcasym.orgHousing and Registration Launch; Abstract Submitter Launch: Late March 2013Abstract Submission Deadline: Tuesday, May 7, 2013, at 11:59 PM (EDT)Quality Care SymposiumNovember 1-3, 2013; San Diego, California; quality.asco.orgHousing and Registration Launch; Abstract Submitter Launch: Mid-May 2013Abstract Submission Deadline: July 2, 2013, at 11:59 PM (EDT)Markers in Cancer: A Joint Meeting by ASCO, EORTC, and NCINovember 7-9, 2013; Brussels, Belgium; markersincancer.eu Diagnostic Development Tutorial: November 5-7, 2013Cancer Center Business SummitOctober 24-25, 2013; Dallas, Texas; cancerbusinesssummit.comUpcoming International MeetingsInternational Clinical Trials WorkshopJune 12-13, 2013; Opatia, Croatia; Croatian Oncology SocietyJune 14-16, 2013; St. Petersburg, Russia; RUSSCOPalliative Care CourseSpring/Summer 2013; Accra, Ghana; AfrOxMultidisciplinary Cancer Management CourseJuly 26-28, 2013; La Paz, Bolivia; OncovidaVisit asco.org/international for details.Leadership Skills SeminarDeveloped specifically to help oncology physicians gain greater insight into key skills needed for success in personal interactions. Visit asco.org/leadership.Spring Course—April 4-5, 2013; Alexandria, VirginiaInterpersonal Communication and Team DynamicsRead the Latest ASCO University® Book ReviewsASCOconnection.org features monthly book reviews of oncology-related titles available in the ASCO University® Bookstore; visit ASCOconnection.org and select "Magazine," then "Book Reviews."Best of ASCO® MeetingsFeaturing practice-changing science and educational highlights from the ASCO Annual Meeting, the Best of ASCO Meetings offer a personal and interactive setting to learn about the latest advances in oncology research and practice.Best of ASCO ChicagoAugust 9-10, 2013Best of ASCO Los AngelesAugust 16-17, 2013Best of ASCO BostonAugust 23-24, 2013Registration and Housing will open in early April. For more information, including a listing of upcoming Best of ASCO International® meetings, visit boa.asco.org.-----------------------Highlights of the 2013 GI and GU Cancers SymposiaIf you missed the Gastrointestinal (GI) Cancers Symposium or the Genitourinary (GU) Cancers Symposium, visit gicasym.org and gucasym.org, respectively, to access Daily News content, including full online versions of print coverage plus bonus online-only live coverage. ascoadmin Tue, 26 Feb 2013 23:37:27 GMT f1397696-738c-4295-afcd-943feb885714:3462 http://connection.asco.org/Magazine/Article/ID/3461/March-2013-Spotlight-on-Education-Oncology-Literature-Reviews.aspx#Comments 0 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=141&ModuleID=498&ArticleID=3461 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=3461&PortalID=0&TabID=141 http://connection.asco.org/Magazine/Article/ID/3461/March-2013-Spotlight-on-Education-Oncology-Literature-Reviews.aspx Courses on Individual Oncology Literature Reviews Now Available for Purchase   Much in the same vein that oncology care providers can deliver the best treatment to patients through personalized medicine, users of ASCO University® can optimize their learning experience by selecting resources that fit their own educational needs. In support of that concept, ASCO University's Oncology Literature Review Series has been updated this year so that users can now select from five individual courses rather than one package with five content areas. Oncology Literature Reviews are quarterly summaries of key papers published in the Journal of Clinical Oncology (JCO) and other major oncology journals. Each course presents users with a trial overview, information on primary results, and discussion of the potential implications for practice. As in previous years, the 2013 Oncology Literature Reviews cover the following topics: breast cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, and lung cancer. The oncology community's growing need for assistance in synthesizing oncology information goes hand-in-hand with the community's increasing need for personalized education. "We understand that health care providers want to individualize their education portfolio," said Joseph J. Muscato, MD, an Oncology Literature Reviews faculty member since the product's inception. "With this new, personalized option for Oncology Literature Reviews, ASCO University is taking an important step in that direction."Overall, the 2013 Oncology Literature Reviews and beyond will "allow reviewers to go into more depth on certain topics, yet those who still want a broader offering will have that option," he said.In addition, providing users with the option to purchase individual courses may alleviate some of the costs of continuing medical education. "We need to help our members by providing programs at various price points. Offering individual Oncology Literature Reviews courses for purchase both maximizes the educational value for users and potentially lowers their expenses," Dr. Muscato added.To access this year's individual Oncology Literature Reviews courses, visit the e-Learning section of university.asco.org and select one of the five cancer topics that correspond to the Series.Oncology Literature Reviews FacultyBREAST CANCERGrace Makari-Judson, MDBaystate Medical CenterErica L. Mayer, MD, MPHHarvard University, Dana-Farber Cancer InstituteGASTROINTESTINAL CANCERSAl B. Benson, III, MD, FACPRobert H. Lurie Comprehensive Cancer Center of Northwestern UniversityJonathan C. Britell, MDSouthlake ClinicGENITOURINARY CANCERSEarle F. Burgess, MDCarolinas HealthCare SystemMarc B. Garnick, MDHarvard University, Beth Israel Deaconess Medical CenterAnthony A. Meluch, MDTennessee Oncology, Sarah Cannon Research InstituteHEMATOLOGIC MALIGNANCIESJustin D. Floyd, DOCape Medical OncologySonali Smith, MDThe University of Chicago Medical CenterLUNG CANCERBenjamin P. Levy, MDBeth Israel Comprehensive Cancer CenterJoseph J. Muscato, MDMissouri Cancer Associates: Columbia CenterRachel E. Sanborn, MDProvidence Cancer CenterAnne S. Tsao, MDThe University of Texas MD Anderson Cancer CenterPlanning Group MembersRonald H. Blum, MDCancer Center at Beth Israel Deaconess Medical CenterBruce J. Roth, MDWashington University School of Medicine ascoadmin Tue, 26 Feb 2013 23:28:30 GMT f1397696-738c-4295-afcd-943feb885714:3461 http://connection.asco.org/Magazine/Article/ID/3457/JOP-Editorial-Addresses-Team-based-Care-in-Oncology.aspx#Comments 0 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=141&ModuleID=498&ArticleID=3457 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=3457&PortalID=0&TabID=141 http://connection.asco.org/Magazine/Article/ID/3457/JOP-Editorial-Addresses-Team-based-Care-in-Oncology.aspx The predicted imbalance between the supply of oncologists and demand for oncology services is a primary concern for those in the field. Accordingly, the March 2013 print issue of the Journal of Oncology Practice (JOP) features an editorial by JOP Editorial Board member David Coniglio, MPA, PA-C, on the importance of team-based care in oncology.“Results of the ASCO Study of Collaborative Practice Arrangements,” by Elaine L. Towle, CMPE; Thomas R. Barr, MBA; Amy Hanley; et al., published in the September 2011 issue of JOP, provides compelling data supporting the use of physician assistants and nurse practitioners in oncology practice, Mr. Coniglio explained. Through his editorial, he hopes to stimulate renewed interest in collaborative care practice models as well as stimulate additional dialogue among practitioners regarding current knowledge, knowledge gaps, and what makes a successful collaborative practice.“If we are going to advance the art and science of caring for patients with cancer, we should be attentive to the changing climate in which we work, and engage ourselves in the continuing work of adapting practice models to patient care needs,” he said.To read the full editorial, visit jop.ascopubs.org. ascoadmin Tue, 26 Feb 2013 18:26:33 GMT f1397696-738c-4295-afcd-943feb885714:3457 http://connection.asco.org/Magazine/Article/ID/3456/New-Consultant-Editor-Joins-JCO.aspx#Comments 0 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=141&ModuleID=498&ArticleID=3456 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=3456&PortalID=0&TabID=141 http://connection.asco.org/Magazine/Article/ID/3456/New-Consultant-Editor-Joins-JCO.aspx Journal of Clinical Oncology (JCO) Editor-in-Chief Stephen A. Cannistra, MD, has created a new editorial position titled Consultant Editor for Medical Education and has named Harold J. Burstein, MD, PhD, FASCO, to assume this role. Dr. Burstein is a clinician and clinical investigator in the Breast Oncology Center at Dana-Farber Cancer Institute and Brigham and Women’s Hospital, as well as an Associate Professor of Medicine at Harvard Medical School. In his JCO role, Dr. Burstein’s responsibilities include overseeing Oncology Grand Rounds (OGR) articles and the podcast program. OGR articles are solicited by the editor and are designed to place original research published in JCO into clinical context for the practicing oncologist. ascoadmin Tue, 26 Feb 2013 18:24:11 GMT f1397696-738c-4295-afcd-943feb885714:3456 http://connection.asco.org/Magazine/Article/ID/3454/JOP-Now-Indexed-in-National-Library-of-Medicines-MEDLINE-Database.aspx#Comments 0 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=141&ModuleID=498&ArticleID=3454 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=3454&PortalID=0&TabID=141 http://connection.asco.org/Magazine/Article/ID/3454/JOP-Now-Indexed-in-National-Library-of-Medicines-MEDLINE-Database.aspx The Journal of Oncology Practice (JOP) was recently accepted for indexing in the U.S. National Library of Medicine’s (NLM’s) premier bibliographic database, MEDLINE, joining the ranks of the highest-quality medical journals.“The Journal of Oncology Practice is honored to be among the stellar journals accepted into MEDLINE,” said John V. Cox, DO, Editor-in-Chief of the Journal. “JOP’s acceptance into MEDLINE extends access to important practice research, trends, and care information to oncologists across the country. This honor further establishes JOP as a journal of growing prominence in oncology and is a reflection of its high-quality content.”MEDLINE is the largest component of PubMed (pubmed.gov), the freely accessible online database of biomedical journal citations and abstracts created by NLM. Approximately 5,400 journals published in the United States and more than 80 other countries have been selected for and are currently indexed for MEDLINE.A distinctive feature of MEDLINE is that the records are indexed with NLM’s controlled vocabulary, the Medical Subject Headings (MeSH). MeSH consists of sets of terms/naming descriptors in a hierarchical structure that permits searching at various levels of specificity.The majority of journals selected for MEDLINE are based on the recommendation of the Literature Selection Technical Review Committee (LSTRC), an NIH-chartered advisory committee of external experts analogous to the committees that review NIH grant applications. Selection for MEDLINE indexing will invariably expose JOP to a wider audience and is a true testament to the quality of its content.In recent commentary on ASCOconnection.org, Dr. Cox wrote: “Ultimately the value of the Journal is dependent on attracting authors who trust that the Journal will evaluate and present their hard work well and in a fashion where their work can be ‘seen’ and commented on. NLM indexing underscores to authors that publication in the Journal of Oncology Practice is a worthy forum for their work.”Visit ASCOconnection.org and select “Commentary,” then John V. Cox, DO, to read the entire post. ascoadmin Tue, 26 Feb 2013 18:20:21 GMT f1397696-738c-4295-afcd-943feb885714:3454 http://connection.asco.org/Magazine/Article/ID/3451/Make-a-Lasting-Difference-Choose-the-Giving-Option-that-Works-For-You.aspx#Comments 0 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=141&ModuleID=498&ArticleID=3451 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=3451&PortalID=0&TabID=141 http://connection.asco.org/Magazine/Article/ID/3451/Make-a-Lasting-Difference-Choose-the-Giving-Option-that-Works-For-You.aspx If you are like the many supporters of the Conquer Cancer Foundation, you may have reached a point where you'd welcome the opportunity to influence not only the future ownership of your possessions, but the meaning that others assign to your life. One way to accomplish this is by considering the means by which you will provide for the people and causes you cherish most. When it comes to defining your legacy at the Conquer Cancer Foundation, your options are numerous. Below are just a few of the ways you can express your values through a gift to help conquer cancer. Donate today. A yearly, monthly, or one-time gift helps provide operational necessities to the Foundation. Include us in your will. Designating the Conquer Cancer Foundation in your will can help create a world free from the fear of cancer. The following sample language can be considered by a donor's estate planners in drafting a simple bequest to the Foundation: "I give [the sum of $ ] OR [ % of my estate] OR [all or % of the rest, residue, and remainder of my estate] to the Conquer Cancer Foundation of the American Society of Clinical Oncology, a Virginia non-stock corporation located at 2318 Mill Road, Suite 800, Alexandria, Virginia, 22314 (Federal Tax ID: 31-1667995), to be used for its general purposes." Establish a life income gift. Receive fixed or variable payments for life and gain valuable tax advantages when you create a life income gift. Donate life insurance. You can easily support our mission by naming the Conquer Cancer Foundation of the American Society of Clinical Oncology as a beneficiary on a policy you already own. Consider your retirement plan assets. By making a simple designation on your plan's beneficiary designation form, you can help the Conquer Cancer Foundation and potentially lessen tax obligations of your loved ones. Please consult with an attorney and other appropriate estate planners when writing your will or making other estate plans. If you have any questions about giving opportunities and the benefits you may receive, contact Teresa Davis Pusztai, Senior Development Officer of Major Gifts (571-483-1455 or teresa.pusztai@conquercancerfoundation) or Sarah Sasman Jacoby, Major Gift Officer (571-451-1456 or sarah.jacoby@conquercancerfoundation.org), or visit conquercancerfoundation.org. ascoadmin Tue, 26 Feb 2013 17:47:39 GMT f1397696-738c-4295-afcd-943feb885714:3451 http://connection.asco.org/Magazine/Article/ID/3450/Awards-Programs-Funded-by-Mission-Endowment.aspx#Comments 0 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=141&ModuleID=498&ArticleID=3450 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=3450&PortalID=0&TabID=141 http://connection.asco.org/Magazine/Article/ID/3450/Awards-Programs-Funded-by-Mission-Endowment.aspx The Foundation's Mission Endowment will provide significant support for grants/awards and ASCO programs this year, including three Young Investigator Awards, an International Innovation Grant, Cancer.Net, Clinical Cancer Advances, the International Cancer Corps, and projects related to palliative care and survivorship. The Foundation thanks the 10 Mission Endowment donors for their generous support: Genentech BioOncologyTM, GlaxoSmithKline Oncology, Novartis Oncology, and Sanofi Oncology (Founding Donors), and Abbott Oncology, Amgen, Celgene Corporation, Eisai Inc., Lilly USA, LLC, Millennium: The Takeda Oncology Company, and Sanofi Oncology (Sustaining Donors). ascoadmin Tue, 26 Feb 2013 17:31:37 GMT f1397696-738c-4295-afcd-943feb885714:3450 http://connection.asco.org/Magazine/Article/ID/3449/Awards-Programs-Funded-by-Mission-Endowment.aspx#Comments 0 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=141&ModuleID=498&ArticleID=3449 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=3449&PortalID=0&TabID=141 http://connection.asco.org/Magazine/Article/ID/3449/Awards-Programs-Funded-by-Mission-Endowment.aspx The Foundation's Mission Endowment will provide significant support for grants/awards and ASCO programs this year, including three Young Investigator Awards, an International Innovation Grant, Cancer.Net, Clinical Cancer Advances, the International Cancer Corps, and projects related to palliative care and survivorship. The Foundation thanks the 10 Mission Endowment donors for their generous support: Genentech BioOncologyTM, GlaxoSmithKline Oncology, Novartis Oncology, and Sanofi Oncology (Founding Donors), and Abbott Oncology, Amgen, Celgene Corporation, Eisai Inc., Lilly USA, LLC, Millennium: The Takeda Oncology Company, and Sanofi Oncology (Sustaining Donors). ascoadmin Tue, 26 Feb 2013 17:31:29 GMT f1397696-738c-4295-afcd-943feb885714:3449 http://connection.asco.org/Magazine/Article/ID/3448/The-Conquer-Cancer-Foundation-of-ASCO-Celebrating-30-Years-of-Young-Investigator-Support.aspx#Comments 0 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=141&ModuleID=498&ArticleID=3448 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=3448&PortalID=0&TabID=141 http://connection.asco.org/Magazine/Article/ID/3448/The-Conquer-Cancer-Foundation-of-ASCO-Celebrating-30-Years-of-Young-Investigator-Support.aspx   Dr. Judith Kaur attends the Grants Alumni Networkng Reception at the 2010 ASCO Annual Meeting.At the 1984 ASCO Annual Meeting in Toronto, Judith Kaur, MD, was presented with the very first Young Investigator Award (YIA), a new program intended to provide grant funding to help young researchers launch their careers in clinical oncology. When the director of her melanoma clinic encouraged Dr. Kaur to apply, she had no idea that she would be the first of many impressive YIA winners to come, but the long-term value of the YIA program became clear when she received the award at what she felt was a "very prestigious event": breakfast with the ASCO President. "The emphasis was that this was just the beginning, that there would be lots of other investigators who could be supported," Dr. Kaur said. "That's why it feels so good to me to have been the first one, that it led to so many more young investigators, young researchers, getting a chance to do good research." It was truly just the beginning, as this year more than 200 early-career researchers have submitted YIA applications. Recipients of the YIA, along with those of the Conquer Cancer Foundation of the American Society of Clinical Oncology's many other awards, will be recognized at the 2013 ASCO Annual Meeting as the Foundation celebrates the 30th anniversary of its Grants and Awards Program. Between 1984 and the 2013 awards cycle, the Conquer Cancer Foundation will have distributed more than $30 million in research funding through its YIA program alone. With nearly 99% of YIA alumni still involved in oncology research, it's clear that the YIA program has been successful in its mission to help clinical investigators launch their research careers and to create a "pipeline" of dedicated, established investigators for future research. In addition, the work of current and past recipients is presented at major medical meetings, published in prestigious journals, and featured in publications such as ASCO's annual Clinical Cancer Advances, which identifies the most practice-changing research of the year. The program has trained generations of oncologists—more than one-quarter of the 2012 YIA recipients had a past YIA recipient as their mentor, and some YIA "families" are already on their third generation. In the past 30 years, the Grants and Awards Program has expanded from bestowing a single YIA to presenting multiple grants and awards that span the continuum of a researcher's career. In 2012, the Conquer Cancer Foundation offered 12 different funding opportunities for oncology professionals at all career levels—medical students through full professors—and for those from academic centers and community practices, from institutions around the globe, and in all areas of translational and clinical cancer research. Rewarding journey "Little did my distinguished colleagues (on the initial ASCO Grant Selection Committee) and I appreciate as we selected Dr. Kaur from among 29 applicants, that we were initiating what has become one of the most successful and rewarding undertakings in ASCO's near 50-year history. Through the generosity and vision of pharmaceutical, foundation, and member sponsors, close to 1,000 grants ranging from the Young Investigator Award to full research professorships have been made, fostering the development of careers, stimulating new knowledge through creative and innovative research, and–ultimately–benefiting countless numbers of patients. I count my involvement in the inception of this program to be one of the professional activities which I am most proud," said Robert J. Mayer, MD, of Dana-Farber Cancer Institute and a member of the original Grants Selection Committee. The Grants and Awards Program and the future of many young researchers would not be possible without support from individuals who believe in the Foundation's vision of creating a world free from the fear of cancer. Join us in improving the care and treatment of people with cancer and in supporting the next 30 years of cancer research at conquercancerfoundation.org/donate. ascoadmin Tue, 26 Feb 2013 17:17:51 GMT f1397696-738c-4295-afcd-943feb885714:3448 http://connection.asco.org/Magazine/Article/ID/3443/New-ASCO-Workforce-Studies-Release-Preliminary-Data-on-Oncology-Workforce-Environment.aspx#Comments 0 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=141&ModuleID=498&ArticleID=3443 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=3443&PortalID=0&TabID=141 http://connection.asco.org/Magazine/Article/ID/3443/New-ASCO-Workforce-Studies-Release-Preliminary-Data-on-Oncology-Workforce-Environment.aspx ASCO has released the preliminary findings of a far-reaching research initiative to collect and analyze oncology workforce demographic and practice data, which reflect a mixed picture of an oncology community adapting to myriad stressors. This initiative will help guide the Society’s response to the ever-changing business and political landscape in which oncologists operate. The following research projects comprise this initiative: The ASCO Workforce Information System (WIS) provides a mechanism for ongoing data collection and reporting on the current status of the oncologist workforce—specifically, for assembling the latest available data on oncologist supply and cancer incidence and prevalence. ASCO plans to publish WIS findings annually, reporting on new data and tracking trends over time. The landmark ASCO National Census of Oncology Practices collected key data from U.S. oncology practices to address a lack of current and reliable information on how oncology practices are adapting to increasing administrative, financial, and political pressures, and to gather information about the existing and trending ownership structure of oncology practices. ASCO will collect, analyze, and report on the census each year, with plans to significantly expand U.S. practice participation in 2013. The ASCO Study of Geographic Access to Oncology Care, contracted with the University of Iowa and with funding from the Susan G. Komen for the Cure®, analyzed data from the Iowa Cancer Registry, providing a means to review all newly diagnosed cancer cases within the entire state to determine if geographic physician distribution and patient access to treatment sites contribute to disparities in cancer care. Iowa was chosen because of its robust physician database and cancer registry. As part of the project, the University of Iowa is helping ASCO understand how to analyze similar treatment trends and geographic distribution of oncologists on a national scale. ASCO plans to expand its research efforts on the state of cancer care and summarize these efforts in an annual report in fall 2013. The original articles on these three studies were published in the January 18, 2013, issue of the Journal of Oncology Practice, and a detailed summary of key findings can be found at asco.org/stateofcancercare. ascoadmin Tue, 26 Feb 2013 00:30:19 GMT f1397696-738c-4295-afcd-943feb885714:3443 http://connection.asco.org/Magazine/Article/ID/3442/QOPI-Participation-May-Satisfy-PQRS-Requirements-in-2014.aspx#Comments 0 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=141&ModuleID=498&ArticleID=3442 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=3442&PortalID=0&TabID=141 http://connection.asco.org/Magazine/Article/ID/3442/QOPI-Participation-May-Satisfy-PQRS-Requirements-in-2014.aspx A provision in the American Taxpayer Relief Act of 2012, which passed in the waning hours of the past year to avert the “fiscal cliff,” may allow oncology practices to meet their Physician Quality Reporting System (PQRS) requirements by participating in ASCO’s Quality Oncology Practice Initiative (QOPI®) starting in 2014. The law, which was signed by President Barack Obama on January 2, allows physicians to meet their federal quality reporting requirements through participation in clinical data registries approved by the U.S. Department of Health and Human Services (HHS). ASCO worked with other medical specialty societies to achieve bipartisan support for this key provision, which begins in 2014 and offers a critical first step toward more robust quality monitoring in cancer care. In the coming months, the Society will provide input to HHS as it develops the criteria and framework to qualify registry programs—such as QOPI—for reporting under the PQRS, administered by the Centers for Medicare and Medicaid Services (CMS). QOPI, a national quality assessment and improvement program involving more than 800 registered oncology practices across the country, is designed to measure care provided in outpatient oncology practices against evidence-based and expert consensus care recommendations, and therefore inform quality improvement activities. Participation in QOPI is voluntary and has been growing steadily since its inception in 2006. Visit ascoaction.asco.org for the latest news on this effort. ascoadmin Tue, 26 Feb 2013 00:25:39 GMT f1397696-738c-4295-afcd-943feb885714:3442 http://connection.asco.org/Magazine/Article/ID/3441/Important-CMS-Reporting-Deadlines-in-2013.aspx#Comments 0 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=141&ModuleID=498&ArticleID=3441 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=3441&PortalID=0&TabID=141 http://connection.asco.org/Magazine/Article/ID/3441/Important-CMS-Reporting-Deadlines-in-2013.aspx Oncologists who don’t participate in the reporting programs of CMS in 2013—specifically, the Physician Quality Reporting System (PQRS), the Electronic Prescribing (eRx) Incentive Program, and the Electronic Health Records (EHR) Incentive Program—run the risk of reductions in Medicare reimbursements on Part B physician fee schedule services. Learn more at asco.org/cmsreporting. ascoadmin Tue, 26 Feb 2013 00:22:34 GMT f1397696-738c-4295-afcd-943feb885714:3441 http://connection.asco.org/Magazine/Article/ID/3440/ASCO-Issues-Recommendations-for-Improving-Cancer-Survivor-Care.aspx#Comments 0 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=141&ModuleID=498&ArticleID=3440 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=3440&PortalID=0&TabID=141 http://connection.asco.org/Magazine/Article/ID/3440/ASCO-Issues-Recommendations-for-Improving-Cancer-Survivor-Care.aspx ASCO recently issued recommendations to help improve the quality of care for the more than 13 million cancer survivors living in the United States. ASCO’s vision for survivorship care comes at a critical time when more people than ever before are surviving cancer as a result of advances in prevention, treatment, and follow- up care. “Most patients still want to see their oncologists even after they have finished active treatment. Oncologists are well positioned to lead and develop a strategy for coordinating follow-up care with primary care providers,” said 2012-2013 ASCO President Sandra M. Swain, MD, FACP. “We can’t let these patients, who are living examples of the progress we have achieved in cancer, fall through the cracks. ASCO’s statement provides a roadmap for closing the gap in survivor care.” ASCO’s survivorship recommendations: Promote patient-centered coordinated care through the use of shared-care models Increase adoption of quality improvement programs, such as QOPI®, which help physicians monitor and improve care for all survivors Expand research on long-term and late effects to develop the evidence base Strengthen the education of health care providers on survivorship care Educate and empower cancer survivors and their families to advocate for their unique needs ASCO is also calling upon policymakers to ensure that the needs of cancer survivors remain a priority as provisions of the Patient Protection and Affordable Care Act are implemented. In addition, ASCO believes the Comprehensive Cancer Care Improvement Act has the capacity to address reimbursement issues related to survivor care by creating a Medicare reimbursement structure for cancer care planning and the development of coordinated cancer care plans. ascoadmin Tue, 26 Feb 2013 00:20:43 GMT f1397696-738c-4295-afcd-943feb885714:3440 http://connection.asco.org/Magazine/Article/ID/3436/ASCO-University-Launches-New-eLearning-Platform.aspx#Comments 0 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=141&ModuleID=498&ArticleID=3436 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=3436&PortalID=0&TabID=141 http://connection.asco.org/Magazine/Article/ID/3436/ASCO-University-Launches-New-eLearning-Platform.aspx ASCO University is the leading online educational resource for oncology professionals, offering a wide range of eLearning activities and self-assessments on a variety of cancer-related topics. ASCO University has moved to a new eLearning platform that has been streamlined to allow for simpler navigation through the extensive catalog of content available. Upon entering the new platform, users will find that courses are now organized under the categories of pending and completed activities which provide for an improved look and feel and easy way to keep track of all education activities. The platform also provides a comprehensive list of additional related content and ASCO University products and resources.Individuals now must select a certificate type for each course as the first step before being able to access the course content. If a certificate is not selected, access will not be granted to the learning activity. Certificates currently available include CME certificates awarding AMA PRA Credit™ for physicians, certificates of participation for physician assistants and nurses, and certificates of completion for all non-CME activities. To identify the appropriate certificate, simply select the arrow on the drop down box beside the “Statement of Credit” option, choose the appropriate certificate, and press the submit button to advance to the appropriate learning activity.From a course perspective, the new eLearning platform provides the advantage of creating a more tailored approach to the individual needs of each learner. Courses include enhanced visual display, with a larger screen view for slide-based content, brief program overviews, continuing education/continuing medical education information and supplementary materials and/or resources relevant to the topic(s) being presented. New courses will also be available in a mobile platform soon. All ASCO Members and other oncology professionals are encouraged to log on and explore these new features the site has to offer.  Visit ASCO University today! ascoadmin Thu, 21 Feb 2013 16:23:10 GMT f1397696-738c-4295-afcd-943feb885714:3436 http://connection.asco.org/Magazine/Article/ID/3432/ASCOs-Health-Disparities-Efforts-Now-Led-by-Standing-ASCO-Committee.aspx#Comments 0 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=141&ModuleID=498&ArticleID=3432 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=3432&PortalID=0&TabID=141 http://connection.asco.org/Magazine/Article/ID/3432/ASCOs-Health-Disparities-Efforts-Now-Led-by-Standing-ASCO-Committee.aspx Despite tremendous improvements to cancer screening and treatment over the last several decades, segments of the American population still experience significant inequities in access to care, quality of care, and cancer outcomes. The elimination of these disparities, particularly among the underserved, uninsured, and minority populations, is critically important for lessening the national burden of cancer. ASCO first began its efforts to address disparities in cancer care more than a decade ago through the work of an advisory group of the ASCO Board. These efforts have led to significant accomplishments (see table below). To reflect the permanent nature of ASCO’s disparities work and more accurately reflect its programmatic scope, in January 2013, the ASCO Board made the decision to change the status of ASCO’s Health Disparities Advisory Group to a standing committee of the Society. The Health Disparities Committee is charged with overseeing ASCO’s portfolio of disparities related initiatives, which are aimed to address the following goals: Education & Awareness: Advance the education of the oncology community in the care of patients from underserved and/or minority populations. Workforce Diversity: Increase the diversity of the clinical oncology workforce as a requisite to improving access to cancer care for the underserved. Research: Support research and the development of clinical cancer researchers in the area of health disparities. Policy & Advocacy: Advocate for policy that ensures access to cancer care for the underserved and that supports increased clinical cancer research in health disparities. Equity: Promote a focus on minority and underserved populations in quality assessment and improvement. “As oncology professionals, we have a responsibility to work toward closing any disparities gaps and to advocate for sound public policies that increase access for all patients with cancer no matter who they are or where they live,” said ASCO President Sandra M. Swain, MD, FACP. Health disparities in cancer outcomes are undoubtedly complex. According to the Institute of Medicine, “the sources of these disparities are complex, are rooted in historic and contemporary inequities and involve many participants at several levels including health systems, their administrative and bureaucratic process, utilization managers, healthcare professionals and patients.” “Only through a combination of efforts—addressing the delivery of care, enhancing the number and training of oncologists caring for diverse populations, and strengthening research on health disparities—can we deliver the significant achievements that are critical to improving care for all,” said ASCO Health Disparities Committee Chair Blase Polite, MD, MPP. As the leading medical society representing physicians engaged in cancer care and research, ASCO recommends that there be no further delay in ensuring that underserved populations receive high quality cancer care. “Achieving health equity for all patient populations will be a long process that will require steps and real input from many partners and stakeholders,” Dr. Polite said. “The formation of this Committee ensures ASCO’s long-term commitment to a health care system where all cancer patients benefit from the tremendous advances being made in cancer care” ASCO’s major health disparities efforts over the past five years include: 2007-2008 Promoted a better understanding on the science of health disparities through Annual Meeting programs. Collaborated with the Oncology Training Programs Committee to develop a strategy to diversify the oncology workforce; launched the Diversity in Oncology Initiative. Highlighted health disparities related content in the Journal of Oncology Practice. 2009-2010 Published ASCO policy statement on disparities in cancer care in Journal of Clinical Oncology Integrated cancer health disparities into ASCO’s guidelines program which include discussion sections of diverse and/or special populations in ASCO guidelines. Facilitated development of an online education module on ASCO University on quality care for minority populations. 2011-2012 Published ASCO policy statement in the Journal of Clinical Oncology on opportunities in the Patient Protection and Affordable Care Act to reduce cancer care disparities. Developed a set of disparities-related questions in ASCO’s Quality Oncology Practice Initiative (QOPI®) to collect demographic data, including the collection of race/ethnicity, insurance status, percentage of non-English speaking patients, and availability of interpretation services Increased policy and advocacy activities by meeting with legislators, joining the Heath Equity and Accountability Act (HEAA) Working Group and providing feedback on the legislation introduced into the Senate. ascoadmin Mon, 11 Feb 2013 19:59:58 GMT f1397696-738c-4295-afcd-943feb885714:3432 http://connection.asco.org/Magazine/Article/ID/3416/Candidates-Invited-to-Apply-for-Editorship-of-ASCO-UniversityASCOs-eLearning-Resource-Center.aspx#Comments 0 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=141&ModuleID=498&ArticleID=3416 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=3416&PortalID=0&TabID=141 http://connection.asco.org/Magazine/Article/ID/3416/Candidates-Invited-to-Apply-for-Editorship-of-ASCO-UniversityASCOs-eLearning-Resource-Center.aspx ASCO is seeking candidates for Editor of ASCO University. The 3-year term will begin in March 2013. ASCO University provides educational products and resources to support lifelong learning among oncology professionals. Education is provided in a variety of digital and online formats and media. The Editor will be responsible for providing leadership and strategic vision for the portfolio of products in ASCO University, as well as editorial oversight for content. Candidates must be ASCO members. Interested candidates or those wishing to nominate a candidate should submit a letter of interest or recommendation, and a curriculum vitae to university@asco.org by January 25, 2013. Selected candidates will receive further information regarding the application process from the ASCO University Editor Search Committee. ascoadmin Thu, 03 Jan 2013 18:21:19 GMT f1397696-738c-4295-afcd-943feb885714:3416 http://connection.asco.org/Magazine/Article/ID/3400/Conquer-Cancer-Foundation-A-Year-of-Accomplishments.aspx#Comments 0 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=141&ModuleID=498&ArticleID=3400 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=3400&PortalID=0&TabID=141 http://connection.asco.org/Magazine/Article/ID/3400/Conquer-Cancer-Foundation-A-Year-of-Accomplishments.aspx The Conquer Cancer Foundation of ASCO achieved numerous milestones and accomplished significant goals in the past year, and looks forward to continued progress in creating a world free from the fear of cancer in 2013. January The Mission Endowment—for the first time since its creation—provided support for Cancer.Net, two Conquer Cancer Foundation Young Investigator Awards, and Cancer Policy and Clinical Affairs, including Survivorship efforts. Twenty recipients of the Gastrointestinal Cancers Symposium Merit Awards supported by CCF presented their abstracts at the Symposium in San Francisco. February Twenty recipients of the Genitourinary Cancers Symposium Merit Awards supported by CCF presented their abstracts at the Symposium in San Francisco. Retained four-star Charity Navigator rating, which is calculated based on a charitable organization’s financial health, transparency, and accountability. Four stars, the highest rating, indicates that the Foundation exceeds industry standards and outperforms other similar organizations in these areas. March Established the James B. Nachman Pediatric Oncology Fund, an endowed fund to support the James B. Nachman ASCO Junior Faculty Award in Pediatric Oncology. The award will be given each year to junior faculty who submit the highest-ranking abstract in pediatric oncology for the ASCO Annual Meeting. May Added Eisai Inc. as a new Sustaining Donor to Mission Endowment. June Recognized the Don Shula Foundation as a supporter for 20 consecutive years. Held the first invitation-only Celebration Dinner honoring CCF’s most generous supporters. Doris Duke Charitable Foundation, a new CCF donor, supported the Medical Student Rotation Awards. July Awarded more than $6 million in research grants and awards to researchers at all career levels. Awarded the first Drug Development Research Professorship to Alex Adjei, MD, PhD. Through this five-year grant, Dr. Adjei will study the development of the toll-like receptor 5 agonist CBLB502 for cancer therapy, and mentor fellows and junior faculty members in drug development. September Won the 2012 Non-Profit Standard of Excellence Award from the Web Marketing Association for conquercancerfoundation.org. Exceeded the Mission Endowment fundraising goal of $2 million. The Endowment was established in 2007 to support the missions of the Foundation and ASCO. Established an endowed Young Investigator Award (YIA) with support from The Breast Cancer Research Foundation (BCRF) in honor and memory of BCRF founder and breast cancer advocate Evelyn H. Lauder. The inaugural award will be presented at the 2013 ASCO Annual Meeting to a physician within the last two years of subspecialty training and planning an investigative career in clinical oncology focused on breast cancer. CCF received its first corporate support for CancerLinQTM, ASCO’s rapid learning system in cancer care: a generous $1 million, five-year gift from Helsinn that will support building the full system that encompasses all cancers. Additional support for CancerLinQ has come from generous donations from Dr. Raj Mantena, Chan Soon-Shiong Family Foundation, Susan G. Komen for the Cure®, and Genentech. Successfully held CCF’s first Challenge Month, which far exceeded the goal of raising $10,000 from individual online donations. With more than $35,000 given by individual donors, and generous matching gifts from the Foundation Board of Directors and Ariad Pharmaceuticals, over $50,000 was raised in a single month. Welcomed Elizabeth A. LaBorde as Chief Development Officer to oversee fundraising operations. Ms. LaBorde has more than 20 years of fundraising and development experience. Prior to joining CCF, she served as Vice President of Development for Make-A-Wish America, and Senior Vice President of Development and Chief Operating Officer of the Children’s Memorial Foundation, the philanthropic arm of the of Ann and Robert H. Lurie Children’s Hospital of Chicago. Sixteen recipients of the Breast Cancer Symposium Merit Awards supported by CCF presented their abstracts at the Symposium in San Francisco. Of the 16 recipients, four are current and former CCF grant and award recipients. October Fourteen recipients of the Markers in Cancer Merit Awards supported by CCF presented their abstracts at the Symposium in Florida. Added Recurring Donation capability to conquercancerfoundation.org. November Twenty recipients of the Quality Care Symposium Merit Awards supported by CCF presented their abstracts at the Symposium in San Diego. These Merit Awards recognize promising oncology researchers for their research examining quality of care. 2012 Raised, in total, more than $23 million to conquer cancer worldwide by funding breakthrough cancer research and sharing cutting-edge knowledge. Over the past year, the Board of Directors of CCF has been greatly diversified, welcoming five new members with backgrounds in philanthropy, law, and business, as well as medicine: Ira Elegant, Esq., a partner in Buchbinder & Elegant, P.A., who has represented several high-profile clients; Michael Gordon, JD, Co-Founder, Chief Operating Officer, and Chief Investment Officer of Angelo, Gordon and Co., an investment advisory firm specializing in alternative investments; Thomas Roberts, Jr., MD, MSocSc, a Managing Member and Portfolio Manager at Farallon Capital Management, LLC; Ann Lurie, an internationally recognized philanthropist; and, Beth Karlan, MD, a leading gynecologic oncologist. ascoadmin Wed, 19 Dec 2012 22:40:06 GMT f1397696-738c-4295-afcd-943feb885714:3400 http://connection.asco.org/Magazine/Article/ID/3397/ASCO-Issues-Annual-Clinical-Cancer-Advances-Report-on-Progress-Against-Cancer.aspx#Comments 0 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=141&ModuleID=498&ArticleID=3397 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=3397&PortalID=0&TabID=141 http://connection.asco.org/Magazine/Article/ID/3397/ASCO-Issues-Annual-Clinical-Cancer-Advances-Report-on-Progress-Against-Cancer.aspx The Society has recently published Clinical Cancer Advances 2012: ASCO's Annual Report on Progress Against Cancer, an independent, comprehensive review of the state of clinical cancer research in 2012. The report highlights advances across the entire continuum of cancer care from prevention to treatment and survivorship. The report also covers a full range of clinical research disciplines, providing expert perspectives on the impact of specific research findings on patient care. "This report shows marked achievements in precision medicine and overcoming treatment resistance," said Bruce J. Roth, MD, Co-Executive Editor of the report. "But tragically, cancer kills more than half a million people each year in the United States alone, and its global burden is rising. Despite difficult economic times, it is absolutely necessary to preserve our nation's investment in cancer research to maintain the pace of discovery that improves outcomes for all people with cancer." Clinical Cancer Advances, now in its eighth year, has served as an educational resource for residents and fellows, placing research in the context of clinical need and drawing attention to open questions where more investigation is needed. Busy practicing oncologists may also look to the document to catch up on the most promising developments and trends outside of their area of expertise. In addition, the report may be used as a quick resource on FDA approvals and clinical practice guidelines for the past year. Many of the top clinical research advances of 2012 involve therapeutic approaches that stem from the oncology community's growing understanding of the complex biology of cancer, which enables development of targeted drugs and treatments tailored to molecular characteristics of individual patients and their tumors. This research has led to seven new FDA approvals for anticancer agents in 2012, some of which will help patients with treatmentresistant forms of cancer. The top advances include: New targeted drugs for patients with advanced colorectal and prostate cancers, skin cancer, and treatmentresistant forms of thyroid cancer and soft tissue sarcoma New combination therapies for patients with breast cancer, chemotherapy-resistant ovarian cancer, esophageal and gastroesophageal junction cancers, and advanced lung cancer A maintenance therapy to delay multiple myeloma relapse A potential new screening modality for colorectal cancer Promising treatments for chemotherapy-induced nausea and pain A predictive model for assessing chemotherapy risks in elderly patients This year's report was compiled and edited under the guidance of 21 renowned experts in specific fields of cancer research. The editors reviewed research published in peer-reviewed scientific or medical journals and presented at major scientific meetings over a one-year period (October 2011-September 2012). Policy developments "The Policy Environment: ASCO in Action in 2012" is a section of the report that outlines important policy developments that have affected oncology over the past year and highlights related ASCO initiatives aimed at creating an environment where faster progress can be made against cancer. Topics covered in this section include: Threats to federal funding of cancer research ASCO's initiative to build a rapid learning system for oncology (CancerLinQ™) ASCO's recommendations to tackle drug shortages Recommendations for improving quality and value in cancer care (Choosing Wisely® campaign and ASCO's Top Five list) The report was published online in the Journal of Clinical Oncology (jco.ascopubs.org) on December 3, 2012. The illustrated version of the report with additional resources is available at cancerprogress.net/cca. Three Conquer Cancer Foundation Grantees Featured in Clinical Cancer Advances A study led by Arti Hurria, MD, (2002 YIA*, 2005 CDA**) reveals factors that predict risk for chemotherapy side effects in older adults and provides a sorely needed tool to inform chemotherapy decision-making for elderly patients. A study led by Paul Paik, MD, (2011 YIA, 2012 CDA) identifies new therapeutic targets for squamous cell lung cancer, which may help hasten the development of targeted drugs for this cancer. A phase II trial led by Mark Dickson, MD, (2009 YIA, 2011 CDA) shows that targeted drug PD0332991 (PD), a CDK4 inhibitor, has promising effects in patients with liposarcoma. *Young Investigator Award **Career Development Award ascoadmin Wed, 19 Dec 2012 20:02:33 GMT f1397696-738c-4295-afcd-943feb885714:3397 http://connection.asco.org/Magazine/Article/ID/3396/Help-Your-Patients-Get-a-Healthy-Start-in-the-New-Year.aspx#Comments 0 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=141&ModuleID=498&ArticleID=3396 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=3396&PortalID=0&TabID=141 http://connection.asco.org/Magazine/Article/ID/3396/Help-Your-Patients-Get-a-Healthy-Start-in-the-New-Year.aspx Many people—including those with cancer—see the beginning of a new year as an opportunity for a fresh start, establishing resolutions to improve health and wellness. To help your patients set and achieve their goals, point them to Cancer.Net, ASCO’s patient information website, where they can learn more about prevention, as well as making healthy changes after a cancer diagnosis. The first place your patients may want to start is in Cancer.Net’s prevention section at cancer.net/prevention. The information in this section is adapted from the ASCO University Curriculum, Cancer Prevention, which includes information on the following topics:Understanding Cancer Risk—explains the concept of risk as it relates to cancer and provides a list of questions about cancer risk that patients can discuss with their doctors.Cancer Screening—discusses the goals and limitations of cancer screening and common cancer screening tests. Chemoprevention—outlines the benefits, risks, and limitations of drugs to reduce the risk of cancer.Diet and Nutrition—provides articles on the link between alcohol and cancer; the role of major nutrients, vitamins, and minerals in cancer prevention; the relationship between plant-based foods and cancer; general nutrition recommendations; and nutrition recommendations during and after cancer treatment. At cancer.net/movingforward, patients can view two videos on the importance of diet and nutrition geared specifically to young adults with cancer.Physical Activity—helps patients understand the role of physical activity in cancer prevention and provides activity recommendations. Weight Control—features information on why maintaining a healthy weight is important for cancer prevention, as well as for recovery from cancer. In addition, Cancer.Net offers podcasts on prevention topics (visit cancer.net/podcasts). Some of the titles include:Pap Test—What to ExpectProtecting Your Skin from the SunWhat is Chemoprevention?HPV and CancerDietary and Herbal SupplementsAlso, several of Cancer.Net’s weekly feature articles offer information on cancer prevention (visit cancer.net/features). Some of these titles include:Colonoscopy—What to ExpectMaking Positive Lifestyle Changes after a Cancer DiagnosisVitamin D and Cancer RiskSeven Steps for a Healthier New YearCancer.Net is supported by the Conquer Cancer Foundation. ascoadmin Wed, 19 Dec 2012 16:14:50 GMT f1397696-738c-4295-afcd-943feb885714:3396 http://connection.asco.org/Magazine/Article/ID/3395/ASCO-Pursues-EHR-Interoperability-Standards-for-Treatment-Summaries.aspx#Comments 0 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=141&ModuleID=498&ArticleID=3395 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=3395&PortalID=0&TabID=141 http://connection.asco.org/Magazine/Article/ID/3395/ASCO-Pursues-EHR-Interoperability-Standards-for-Treatment-Summaries.aspx In response to national requirements for providers who care for Medicare and Medicaid recipients, use of electronic health records (EHRs) is increasing. However, health care has not created and adopted one comprehensive standard that supports information exchange for the breadth of clinical information. Even with EHRs and other software applications, much of the information still cannot be easily shared across software applications and between providers. The difficulty in exchanging clinical data is compounded by the fact that many providers still document some or all of the clinical notes on paper. Data that cannot be shared electronically is difficult and resource-intensive to manually abstract for research, quality, or public health reporting. Thus, ASCO initiated a project in August 2012 to develop oncology data standards that will promote interoperability and exchange of critical information among providers and patients.Members of ASCO’s Health Information Technology Work Group are focusing on defining an interoperability standard for the data in ASCO’s Breast Cancer Adjuvant Treatment Plan and Summary as an initial step to enhance electronic information exchange. In 2013, the completed standard will be tested and validated to ensure that it reflects the clinical information accurately, and an implementation guide will be published to assist with vendor adoption.In alignment with the Office of the National Coordinator regulations, ASCO is working through the Health Level Seven (HL7) process to develop the oncology standards. HL7 is a certified standards development organization that defines international standards for health information technology. For more information, visit asco.org/EHR. ascoadmin Wed, 19 Dec 2012 15:59:14 GMT f1397696-738c-4295-afcd-943feb885714:3395 http://connection.asco.org/Magazine/Article/ID/3394/ASCO-Announces-New-Chief-Medical-Officer.aspx#Comments 0 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=141&ModuleID=498&ArticleID=3394 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=3394&PortalID=0&TabID=141 http://connection.asco.org/Magazine/Article/ID/3394/ASCO-Announces-New-Chief-Medical-Officer.aspx ASCO recently announced the formation of an important new position within ASCO, that of a Chief Medical Officer (CMO). After a six-month search, a five-person committee comprised of ASCO Board of Directors members chose Richard L. Schilsky, MD, to fulfill this key role. Dr. Schilsky comes to ASCO as Chief of Hematology/Oncology in the Department of Medicine and Deputy Director of the University of Chicago Comprehensive Cancer Center. He will be joining the ASCO staff on February 28, 2013. Dr. Schilsky is a former ASCO president (2008-2009) and a highly respected leader in the field of clinical oncology, specializing in new drug development and treatment of gastrointestinal cancers. As a past Board member; former Chair of ASCO's Cancer Research, Communications, and Government Relations Committees; and a current member of the Conquer Cancer Foundation Board, Dr. Schilsky brings with him a firm grasp of the organization including its history, mission, structure, and operations. The Chief Medical Officer position will report directly to the CEO, Allen S. Lichter, MD, and support the President, volunteer leadership, CEO, and staff in communicating and carrying out the overall strategic priorities of the organization."Rich has that rare combination of clinical expertise, a formidable research track record, and a warmth and humanity that make him perfect for this role," said Sandra M. Swain, MD, FACP, ASCO President and Chair of the CMO Search Committee. "Having led many of ASCO's most important efforts and committees over the years, he is also intimately familiar with ASCO's programs, staff, and member needs. As President, I look forward to working with him. I am sure he will provide wise counsel as we advance ASCO's mission." Expanded efforts ASCO has branched into new areas in recent years, and the Board decided it was time to bring on another experienced senior member of the staff leadership team to provide additional insight and guidance. "I look forward to welcoming Rich to our team during this very exciting time in cancer science and this very challenging time in cancer medicine when all of us must look harder at the quality and value of care we provide," said Dr. Lichter. ascoadmin Wed, 19 Dec 2012 15:54:07 GMT f1397696-738c-4295-afcd-943feb885714:3394 http://connection.asco.org/Magazine/Article/ID/3393/New-Oral-Chemotherapy-Safety-Standards-Approved.aspx#Comments 0 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=141&ModuleID=498&ArticleID=3393 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=3393&PortalID=0&TabID=141 http://connection.asco.org/Magazine/Article/ID/3393/New-Oral-Chemotherapy-Safety-Standards-Approved.aspx ASCO and the Oncology Nursing Society (ONS) have been working jointly over the past year to augment the existing ASCO/ONS Standards for Safe Chemotherapy Administration with additional standards focused on oral chemotherapy administration. This work recognizes the expansion of the use of oral agents in the oncology office and the special safety concerns related to these agents. The development methodology for the oral chemotherapy safety standards included a multi-stakeholder consensus meeting, an open public comment period, and review by the ASCO and ONS Boards of Directors. The standards were approved by ASCO and ONS in November 2012 and will be published in 2013. For more information, visit asco.org/safety. ascoadmin Wed, 19 Dec 2012 15:53:37 GMT f1397696-738c-4295-afcd-943feb885714:3393 http://connection.asco.org/Magazine/Article/ID/3392/Oral-Parity-Laws-Assisting-Patients-with-the-Financial-Burdens-of-Cancer-Drugs.aspx#Comments 0 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=141&ModuleID=498&ArticleID=3392 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=3392&PortalID=0&TabID=141 http://connection.asco.org/Magazine/Article/ID/3392/Oral-Parity-Laws-Assisting-Patients-with-the-Financial-Burdens-of-Cancer-Drugs.aspx By Steven Stranne, ASCO Policy CounselWith the introduction of a number of highly effective oral cancer drugs over recent years, oncology professionals have witnessed an increasing number of troubling circumstances in which individuals with health insurance are unable to afford the most appropriate cancer therapy. To help address this, ASCO members and staff have been successful in working to support efforts to promote oral parity legislation at state and federal levels.Legislatures in 20 states and the District of Columbia have enacted laws to help ensure parity between oral and intravenous cancer drugs, including state laws enacted in 2012 in Delaware, Louisiana, Maryland, Nebraska, New Jersey, and Virginia. Bills have also been introduced in at least a dozen other states.The phrase “oral parity” refers to legislative initiatives intended to protect patients with cancer from high cost-sharing requirements that are sometimes associated with oral cancer drugs under health insurance plans. In many instances, individuals with health insurance face much higher cost-sharing requirements for oral cancer drugs than for intravenous or injected drugs administered in an office, clinic, or hospital setting.The differences in cost-sharing arise from the typical structure of benefits under most health plans. Most intravenous and injected cancer drugs administered by a health care professional are covered under the medical benefit of a health insurance product. In contrast, most oral cancer drugs are covered under the prescription drug benefit. The cost-sharing requirements for patients (which can take the form of deductibles, copayments, coinsurance, and dollar limits) are often lower under the medical benefit and higher under the prescription drug benefit. In many instances, the most expensive oral cancer drugs are placed on a top tier of the prescription drug formulary, resulting in the highest possible cost-sharing requirements.The need to protect patients against these unaffordable cost-sharing burdens has become more acute over the past several years. The introduction of new oral cancer drugs has provided options that in many instances represent significant clinical advantages over traditional intravenous/injected forms of cancer treatment. In some instances, oral cancer drugs represent the only viable treatment.Oral parity bills typically have three components. First, the bills establish safeguards to ensure that patients can access oral cancer drugs under the same general cost-sharing rules as other cancer drugs, including intravenous/injected cancer drugs. Second, the bills define patient cost-sharing to include such obligations as patient copayments, coinsurance, deductibles, and dollar limits. Third, the bills attempt to create safeguards to prevent insurers from circumventing the intent of the legislation by reclassifying intravenous drugs or by other means. Oral parity bills are intended to provide targeted relief to individuals. As a result, there are no provisions that involve reimbursement for oncologists, pharmacists, or other health care providers.Educating policymakersOncologists and other cancer care specialists have a unique role to play in educating policymakers about the need to protect patient access to oral cancer drugs. Our members can explain the critical clinical importance of securing patient access to oral cancer drugs and provide real-world examples of how these policies affect the clinical outcomes and lives of patients, emphasizing that access to oral cancer drugs is not merely an issue of convenience for patients or health care providers.State oral parity laws are designed to govern the health insurance products that are subject to oversight by state insurance regulators. However, state insurance laws generally do not apply to self-insured employers, which are subject to the federal Employment Retirement Income Security Act (ERISA). There are a significant number of patients with cancer who are covered by ERISA health plans, as roughly 80% of employer-based health care coverage is governed by ERISA. Currently, ASCO is working with Members of Congress on federal legislation that would apply oral parity safeguards to the health insurance provided by self-insured (ERISA) employer plans.ASCO has developed model legislation and other materials to assist advocates working to support these initiatives. For more information, contact ASCO’s Cancer Policy & Clinical Affairs Department at 571-483-1670 or publicpolicy@asco.org. ascoadmin Wed, 19 Dec 2012 15:51:26 GMT f1397696-738c-4295-afcd-943feb885714:3392 http://connection.asco.org/Magazine/Article/ID/3387/January-2013-Spotlight-on-Education-Meetings.aspx#Comments 0 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=141&ModuleID=498&ArticleID=3387 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=3387&PortalID=0&TabID=141 http://connection.asco.org/Magazine/Article/ID/3387/January-2013-Spotlight-on-Education-Meetings.aspx 2013 Gastrointestinal Cancers SymposiumCelebrating Ten YearsJanuary 24-26, 2013; San Francisco, California; gicasym.org2013 Genitourinary Cancers SymposiumA Transformative Multidisciplinary ApproachFebruary 14-16, 2013; Orlando, Florida; gucasym.orgDaily News to Feature Online Live Coverage at GI and GU SymposiaOnsite coverage will be posted throughout each day of the Gastrointestinal Cancers and Genitourinary Cancers Symposia along with exclusive Virtual Meeting clips, Twitter feeds, and exclusive video interviews with faculty. Visit gicasym.org and gucasym.org for more information.2013 ASCO Annual MeetingMay 31–June 4, 2013; Chicago, Illinois; chicago2013.asco.orgAbstract Submission Deadline: February 5, 2013, 11:59 PM (EST); visit asco.org/cfaAccess preliminary program information at chicago2013.asco.orgCore Session MOC Self-Assessment ActivityNew this year, the Annual Meeting Core Session Maintenance of Certification (MOC) Self-Assessment activity is designed for Annual Meeting attendees who want to refresh their knowledge, update their skills, or simply prepare for their board certification or MOC examination. Registration includes access to an online pre-examination intended to highlight areas of educational need, a list of suggested Core Sessions to attend to fill knowledge gaps, and an online post-examination. After successful completion of the post-examination, participants will be eligible to claim 10 MOC points in Self-Assessment of Medical Knowledge.Pre-Annual Meeting SeminarsASCO is offering four in-depth educational opportunities dedicated to topics of interest in the oncology community, including:New Drugs in OncologyClinical Care in Oncology for the Advanced Practice ProviderDesigns in Contemporary Early-Phase Clinical TrialsGenetics and Genomics for CliniciansThese one-day seminars are not part of the official ASCO Annual Meeting program, but will be held onsite at McCormick Place. Attendees can register for the seminars as part of their Annual Meeting registration by visiting chicago2013.asco.org.Save the Date: 2013 Best of ASCO®2013 Best of ASCO domestic meetings will be held in three locations; visit boa.asco.org for details.Best of ASCO ChicagoAugust 9-10, 2013Chicago, IllinoisBest of ASCO Los AngelesAugust 16-17, 2013Los Angeles, CaliforniaBest of ASCO BostonAugust 23-24, 2013Boston, MassachusettsUpcoming International MeetingsClinical Research WorkshopMethods in Cancer Research WorkshopFebruary 9-13, 2013; Saudi Arabia; King Abdulaziz City for Science and Technology, King Abdullah International Medical Research CenterInternational Clinical Trials WorkshopJune 12-13, 2013; Opatia, Croatia; Croatian Oncology SocietyJune 14-16, 2013; St. Petersburg, Russia; RUSSCOMultidisciplinary Cancer Management CourseJanuary 21-24, 2013; Eldoret, Kenya; AMPATHPalliative Care WorkshopFebruary 10-13, 2013; Muscat, Oman; MECCFebruary 14-16, 2013; Mexico City, Mexico; National Cancer Institute (INCAN)Visit asco.org/international for details.Follow Meetings on TwitterGastrointestinal Cancers Symposium—#GI13Genitourinary Cancers Symposium—#GU13ASCO Annual Meeting—#ASCO13 ascoadmin Tue, 18 Dec 2012 19:17:55 GMT f1397696-738c-4295-afcd-943feb885714:3387 http://connection.asco.org/Magazine/Article/ID/3385/JCO-Article-Examines-Chemotherapy-and-Cognitive-Deficits.aspx#Comments 0 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=141&ModuleID=498&ArticleID=3385 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=3385&PortalID=0&TabID=141 http://connection.asco.org/Magazine/Article/ID/3385/JCO-Article-Examines-Chemotherapy-and-Cognitive-Deficits.aspx Anecdotal reports of a loss of mental acuity are a source of significant concern among patients with cancer treated with chemotherapy. Although cognitive deficits are pronounced during treatment, data are conflicting regarding the persistence of cognitive deficits after treatment.In a recent meta-analysis examining 17 studies of 807 patients previously treated with standard-dose chemotherapy for breast cancer, observed cognitive effects tend to be, on average, small in magnitude and limited to verbal and visuospatial ability, according to the October 10, 2012, Journal of Clinical Oncology (JCO) article, “Meta-Analysis of Cognitive Functioning in Breast Cancer Survivors Previously Treated with Standard-Dose Chemotherapy.”“This information can be used to inform interventions to educate patients with breast cancer regarding the long-term impact of chemotherapy on cognitive functioning,” as stated in the report by study authors Heather S.L. Jim, PhD; Kristin M. Phillips, PhD; Sari Chait, MD, PhD, et al.For more information on the report, visit jco.ascopubs.org. An accompanying JCO podcast, “In a Sea of Data the Water Is Still Murky: Meta-Analysis of Cognition in Breast Cancer,” by Janette L. Vardy, MD, PhD, is also available at jco.ascopubs.org. ascoadmin Tue, 18 Dec 2012 17:15:31 GMT f1397696-738c-4295-afcd-943feb885714:3385 http://connection.asco.org/Magazine/Article/ID/3384/JOP-Explores-Effort-Required-for-Cancer-Clinical-Trials-Screening.aspx#Comments 0 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=141&ModuleID=498&ArticleID=3384 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=3384&PortalID=0&TabID=141 http://connection.asco.org/Magazine/Article/ID/3384/JOP-Explores-Effort-Required-for-Cancer-Clinical-Trials-Screening.aspx Identifying eligible patients for clinical trials represents one of the most challenging and important components in the accrual process, yet most sponsors typically do not reimburse for the eligibility screening process.In the November 2012 Journal of Oncology Practice (JOP) article, “Effort Required in Eligibility Screening for Clinical Trials,” authors Lynne T. Penberthy, MD, MPH; Bassam A. Dahman, PhD; Valentina I. Petkov, MD, MPH, et al., summarize their efforts using a real-time tracking system to capture clinical trial evaluations and also outline information on evaluation outcomes and time spent on each eligibility screening by research staff. Specifically, the article includes tables that outline: a distribution of evaluations according to patient characteristics, a distribution of the proportion of evaluations according to the level of effort and by nonpatient characteristics, and an estimated time per evaluation and per enrollment and the associated cost. Authors concluded that “the cost of recruiting patients to [clinical trials] is high, with most studies not fully covering the cost of the trial itself.” Eligibility screening can be a significant financial burden to an institution, especially if the institution is performing early-phase clinical trials. Accordingly, the information presented in the article “could serve as a point of negotiation with sponsors to reduce the gap between reimbursed and unreimbursed costs.”Visit jop.ascopubs.org for more information. ascoadmin Tue, 18 Dec 2012 17:00:17 GMT f1397696-738c-4295-afcd-943feb885714:3384 http://connection.asco.org/Magazine/Article/ID/3363/Stopping-Tobacco-Use-after-a-Cancer-Diagnosis.aspx#Comments 0 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=141&ModuleID=498&ArticleID=3363 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=3363&PortalID=0&TabID=141 http://connection.asco.org/Magazine/Article/ID/3363/Stopping-Tobacco-Use-after-a-Cancer-Diagnosis.aspx ASCO offers a booklet to help patients and physicians understand the benefits of stopping tobacco use in the context of a cancer diagnosis. This booklet is a companion to ASCO’s information for providers on tobacco cessation. It explains the information patients should communicate to their doctor about their tobacco use and lists the health benefits of quitting, various methods patients can use to aid the process, as well as resources such as help lines and mobile apps. Send your patients to cancer.net/tobacco to learn more. ascoadmin Wed, 31 Oct 2012 19:11:39 GMT f1397696-738c-4295-afcd-943feb885714:3363 http://connection.asco.org/Magazine/Article/ID/3360/New-ASCO-Resources-Help-Oncologists-Discuss-Tobacco-Cessation.aspx#Comments 0 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=141&ModuleID=498&ArticleID=3360 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=3360&PortalID=0&TabID=141 http://connection.asco.org/Magazine/Article/ID/3360/New-ASCO-Resources-Help-Oncologists-Discuss-Tobacco-Cessation.aspx In keeping with its goals to improve patients’ health and enhance the knowledge and training of oncology providers, ASCO released a new set of resources for tobacco cessation counseling. The evidence-based Tobacco Cessation Guide for Oncology Providers describes practical steps for educating patients about the negative effects of tobacco use on cancer treatment outcomes and to help them quit. The guide, accompanied by a take-home booklet for patients, addresses the growing need for instruction on how to effectively integrate tobacco cessation into routine patient care and how to overcome barriers to practice.“It is well recognized that tobacco use increases the risks of several kinds of cancers. However, patients are often not aware of the effects that continued tobacco use can have on their cancer treatment outcomes,” said K. Michael Cummings, PhD, member of ASCO’s Tobacco Control Subcommittee and Professor at the Medical University of South Carolina Hollings Cancer Center. “As oncology providers, we have a responsibility to assist patients’ efforts to cease tobacco use, since not smoking will improve the success of the cancer therapies we offer to our patients.”Using this resource, oncology providers will be able to explain the importance of tobacco cessation, identify ways to help their patients quit, and obtain appropriate reimbursement for the tobacco cessation services theyprovide.The provider guide and patient booklet are available for purchase in the ASCO University Bookstore, and available to download at asco.org/tobaccocessationguide and cancer.net/tobacco. ascoadmin Tue, 30 Oct 2012 17:12:22 GMT f1397696-738c-4295-afcd-943feb885714:3360 http://connection.asco.org/Magazine/Article/ID/3359/ASCO-Decision-Aids-Intersect-Evidence-Based-Guidelines-Productive-Patient-Communication.aspx#Comments 0 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=141&ModuleID=498&ArticleID=3359 http://connection.asco.org/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=3359&PortalID=0&TabID=141 http://connection.asco.org/Magazine/Article/ID/3359/ASCO-Decision-Aids-Intersect-Evidence-Based-Guidelines-Productive-Patient-Communication.aspx By Sarah Temin, MSPH, ASCO Guidelines Resource Specialist Imagine this common clinical scenario: A 64-year-old woman presents with a new abnormality on a mammogram. A core needle biopsy and subsequent partial mastectomy reveal a 1.8-cm invasive ductal carcinoma. Sentinel lymph nodes are negative for cancer. The tumor is moderately differentiated and is estrogen receptor–positive, progesterone receptor–positive, and HER2- negative. Oncotype DX testing reveals a recurrence score of 12 (low risk). The patient completes postlumpectomy radiation and now presents to your clinic to discuss adjuvant anti-estrogen strategies. What are the treatment options? How do you present them clearly to your patient? And how do you ensure that she is a partner in decision-making? ASCO Decision Aids can facilitate these discussions (asco.org/clinicaltools). These tools are based on the science in ASCO’s evidence-based clinical practice guidelines and incorporate the best practices of decision aid development (see Additional Reading). They allow a clinician to display and explain information on risk and benefits, and help the patient to think about his or her own values and preferences. Research suggests that the use of decision aids increases patient knowledge without increasing anxiety and can increase patient satisfaction. Bridging the gap to shared decision-making Decision aids can streamline the decision-making process and their use frequently leads to a finalized decision about care. “When I have used the ASCO Adjuvant Endocrine Therapy Decision Aid with women in my practice, it has cut down on the number of times I’ve received follow-up phone calls,” said Michael A. Danso, MD, of Virginia Oncology Associates and ASCO Practice Guidelines Implementation Network (PGIN) Co-Chair. In the scenario described in the first paragraph, the patient has more than one treatment option (outlined in the ASCO Guideline Update on Adjuvant Endocrine Therapy for Women with Hormone Receptor–Positive Breast Cancer). The options carry benefits and risks, and none is clearly superior— a frequent experience in oncology. Patients in this situation may experience feelings of uncertainty, difficulty identifying the best option, and concern that they will regret their choice (“decisional conflict”). Although clinical practice guidelines and clinical trials may guide the clinician, guidelines and study results are typically not written with a patient audience in mind, and circumstances may constrain the clinician in explaining them. Decision aids help to bridge this gap and lead to shared decision-making. For example, the ASCO Decision Aid for this scenario includes data showing potential benefits and risks or harms of tamoxifen, aromatase inhibitors, or a sequential combination. It appeals to a variety of learning styles, including visual and auditory. Graphics are formatted to quickly and comprehensibly communicate data in text and pictographs. After the visit, the patient can use the Decision Aid’s worksheet, based on the Ottawa Personal Decision Guide, to reflect on the discussion, plan next steps (such as seeking support from others), and make the best choice for her. ASCO Decision Aids are available for adjuvant endocrine therapy and risk reduction in breast cancer, and adjuvant treatment and treatment of advanced disease in non-small cell lung cancer. "This information allows me to give my patients a more complete picture of the treatment regimen, potential benefits, and risks, including an excellent summary table on potential chemotherapy toxicities," said James N. Frame, MD, of Charleston Area Medical Center and PGIN Co-Chair, who uses the ASCO Decision Aid on the treatment of advanced non-small cell lung cancer in his practice. Additional Reading 1. O’Brien MA, Whelan TJ, Villasis-Keever M, et al. Are cancer-related decision aids effective? A systematic review and meta-analysis. J Clin Oncol. 2009;6:974-85. PMID: 19124808. 2. O’Connor A, Jacobsen MJ, Stacey D. An evidence-based approach to managing women’s decisional conflict. J Obstet Gynecol Neonatal Nurs. 2002;31;570-81. PMID: 12353737. 3. Barry MJ, Edgman-Levitan S. Shared decision making—pinnacle of patient-centered care. N Engl J Med. 2012;366:780-1. PMID: 22375967 4. Fagerlin A, Zikmund-Fisher BJ, Ubel PA. Helping patients decide: ten steps to better risk communication. J Natl Cancer Inst. 2011;103:1436-43. PMID: 21931068. 5. Stacey D, Bennett CL, Barry MJ, et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev. 2011;(10):CD001431. PMID: 21975733. ascoadmin Tue, 30 Oct 2012 17:00:44 GMT f1397696-738c-4295-afcd-943feb885714:3359